WO2022178594A1 - C-reactive protein inhibitors - Google Patents
C-reactive protein inhibitors Download PDFInfo
- Publication number
- WO2022178594A1 WO2022178594A1 PCT/AU2022/050156 AU2022050156W WO2022178594A1 WO 2022178594 A1 WO2022178594 A1 WO 2022178594A1 AU 2022050156 W AU2022050156 W AU 2022050156W WO 2022178594 A1 WO2022178594 A1 WO 2022178594A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- disease
- reactive protein
- pharmaceutically acceptable
- Prior art date
Links
- 108010074051 C-Reactive Protein Proteins 0.000 title claims abstract description 82
- 102100032752 C-reactive protein Human genes 0.000 title claims abstract description 82
- 229940121649 protein inhibitor Drugs 0.000 title description 2
- 239000012268 protein inhibitor Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 122
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 53
- 201000010099 disease Diseases 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 32
- 206010061218 Inflammation Diseases 0.000 claims abstract description 23
- 230000004054 inflammatory process Effects 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 208000035475 disorder Diseases 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000000770 proinflammatory effect Effects 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims description 69
- 239000012453 solvate Substances 0.000 claims description 58
- 206010063837 Reperfusion injury Diseases 0.000 claims description 14
- 238000001356 surgical procedure Methods 0.000 claims description 13
- 238000002054 transplantation Methods 0.000 claims description 13
- 208000027866 inflammatory disease Diseases 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 9
- 229910018830 PO3H Inorganic materials 0.000 claims description 8
- 229910006069 SO3H Inorganic materials 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 8
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 210000000056 organ Anatomy 0.000 claims description 7
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 208000025721 COVID-19 Diseases 0.000 claims description 5
- 206010040047 Sepsis Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 206010002023 Amyloidoses Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 208000021709 Delayed Graft Function Diseases 0.000 claims description 3
- 206010028851 Necrosis Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000024777 Prion disease Diseases 0.000 claims description 3
- 206010061481 Renal injury Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 230000003143 atherosclerotic effect Effects 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000017074 necrotic cell death Effects 0.000 claims description 3
- 208000008494 pericarditis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000037816 tissue injury Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 238000007631 vascular surgery Methods 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 208000025747 Rheumatic disease Diseases 0.000 claims description 2
- 208000038018 age-related macular disease Diseases 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 4
- 229940125904 compound 1 Drugs 0.000 description 45
- 239000000203 mixture Substances 0.000 description 33
- 241000700159 Rattus Species 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- -1 amino compound Chemical class 0.000 description 27
- 210000002700 urine Anatomy 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 125000001072 heteroaryl group Chemical group 0.000 description 13
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 12
- 206010057249 Phagocytosis Diseases 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000004122 cyclic group Chemical group 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 230000008782 phagocytosis Effects 0.000 description 11
- 125000000217 alkyl group Chemical group 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000011436 cob Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 210000003141 lower extremity Anatomy 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 7
- 229910052796 boron Inorganic materials 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 210000005084 renal tissue Anatomy 0.000 description 7
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 210000001589 microsome Anatomy 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 241000700157 Rattus norvegicus Species 0.000 description 5
- 125000002877 alkyl aryl group Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 241000283984 Rodentia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 229920000392 Zymosan Polymers 0.000 description 4
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000003364 immunohistochemistry Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N methylimidazole Natural products CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000010410 reperfusion Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- IEGDTPSLUJHTLA-UHFFFAOYSA-N CCCCN(CCCC)CCCP(OCC)(OCC)=O Chemical compound CCCCN(CCCC)CCCP(OCC)(OCC)=O IEGDTPSLUJHTLA-UHFFFAOYSA-N 0.000 description 3
- NEIXPXGLNXWMIF-UHFFFAOYSA-N CCOP(CCCN(CC1=CC=CC=C1)CC1=CC=CC=C1)(OCC)=O Chemical compound CCOP(CCCN(CC1=CC=CC=C1)CC1=CC=CC=C1)(OCC)=O NEIXPXGLNXWMIF-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 3
- 102100025136 Macrosialin Human genes 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000024203 complement activation Effects 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229910052717 sulfur Chemical group 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000000451 tissue damage Effects 0.000 description 3
- 231100000827 tissue damage Toxicity 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- FSSPGSAQUIYDCN-UHFFFAOYSA-N 1,3-Propane sultone Chemical compound O=S1(=O)CCCO1 FSSPGSAQUIYDCN-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XXIKKBPTWQTKFG-UHFFFAOYSA-N 3-(dibenzylamino)propane-1-sulfonic acid Chemical compound C=1C=CC=CC=1CN(CCCS(=O)(=O)O)CC1=CC=CC=C1 XXIKKBPTWQTKFG-UHFFFAOYSA-N 0.000 description 2
- ZYSWPMOWJRKDEZ-UHFFFAOYSA-N 3-(dibutylamino)propane-1-sulfonic acid Chemical compound CCCCN(CCCC)CCCS(O)(=O)=O ZYSWPMOWJRKDEZ-UHFFFAOYSA-N 0.000 description 2
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XATRQYYMOIGUKL-UHFFFAOYSA-N CCCCN(CCCC)CCCP(O)(O)=O Chemical compound CCCCN(CCCC)CCCP(O)(O)=O XATRQYYMOIGUKL-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 2
- PEIKTSJIUKYDPC-UHFFFAOYSA-N Diethyl 3-Bromopropylphosphonate Chemical compound CCOP(=O)(OCC)CCCBr PEIKTSJIUKYDPC-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 206010048748 Graft loss Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 2
- 101000922020 Homo sapiens Cysteine and glycine-rich protein 1 Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- LPZBMZQRNHBMKY-UHFFFAOYSA-N OP(CCCN(CC1=CC=CC=C1)CC1=CC=CC=C1)(O)=O Chemical compound OP(CCCN(CC1=CC=CC=C1)CC1=CC=CC=C1)(O)=O LPZBMZQRNHBMKY-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010063897 Renal ischaemia Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 102000051143 human CRP Human genes 0.000 description 2
- DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- AUCGNAJVFOZTHS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=C=N[CH]1 AUCGNAJVFOZTHS-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010051392 Diapedesis Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N alpha-methylpyridine Natural products CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- ITQTTZVARXURQS-UHFFFAOYSA-N beta-methylpyridine Natural products CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- PQZTVWVYCLIIJY-UHFFFAOYSA-N diethyl(propyl)amine Chemical group CCCN(CC)CC PQZTVWVYCLIIJY-UHFFFAOYSA-N 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical group CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 239000012713 reactive precursor Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000008698 shear stress Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical group CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- PWYVVBKROXXHEB-UHFFFAOYSA-M trimethyl-[3-(1-methyl-2,3,4,5-tetraphenylsilol-1-yl)propyl]azanium;iodide Chemical compound [I-].C[N+](C)(C)CCC[Si]1(C)C(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 PWYVVBKROXXHEB-UHFFFAOYSA-M 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000013389 whole blood assay Methods 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Definitions
- the present disclosure relates to functionalized amino compounds that can provide inhibitors of C-reactive protein (CRP).
- CRP C-reactive protein
- the present disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of CRP associated diseases, disorders or conditions, and particularly the treatment of inflammation associated with pro-inflammatory effects of CRP, and to related uses.
- IRI Ischemia/reperfusion injury
- ROS reactive oxygen species
- the present inventors have recently identified pro-inflammatory effects of CRP associated with inflammatory response. Accordingly, there remains a need to develop safe and efficacious inihbitors of CRP for controlling associated inflammation.
- the present inventors have undertaken extensive research into the development of inhibitors of CRP and have surprisingly identified functionalized amino compounds effective for modulating or inhibiting CRP associated inflammatory effects.
- the present disclosure provides an amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
- X 1 is selected from -SO 3 H, -PO 3 H, and -CO2H;
- L 1 is selected from -CH2-CH2-, -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, -O-CH2-CH2-, -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-; and
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- the present disclosure provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples as described herein, and a pharmaceutically acceptable excipient.
- the present disclosure provides a method of controlling C-reactive protein levels in a subject comprising administering to the subject an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples as described herein.
- the controlling of C- reactive protein levels in a subject can be by modulating or inhibiting the pro-inflammatory actions of CRP, and in particular bioactive conformations of pentameric C-reactive protein (pCRP*) or monomeric C-reactive protein (mCRP).
- the present disclosure provides a method of preventing or treating a C-reactive protein associated disease, disorder or condition, comprising administering to a subject in need of treatment thereof an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples thereof as described herein.
- the present disclosure provides the use of a compound of Formula 1, salt, solvate or stereoisomer, or of the pharmaceutical composition, according to any aspects, embodiments or examples thereof as described herein, in the manufacture of a medicament for modulating or inhibiting C-reactive protein levels in a subject.
- the C-reactive protein associated disease, disorder or condition is an ischemia-reperfusion injury including myocardial infarction, stroke, organ or vascular transplants, surgery or injuries, bums, allogenic transplantation, atherosclerotic disease, pericarditis, miocarditis, autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, or diseases associated with inflammation driven by protein misfolding such as amyloidoses, Alzheimer disease, prion diseases and age-related macular degeneration, or diseases associated with overshooting inflammation such as sepsis or COVID-19.
- ischemia-reperfusion injury including myocardial infarction, stroke, organ or vascular transplants, surgery or injuries, bums, allogenic transplantation, atherosclerotic disease, pericarditis, miocarditis, autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, or diseases
- the term about refers to +/- 20%, more preferably +/- 10%, of the designated value.
- the term “subject” refers to any organism susceptible to a disease or condition.
- the subject can be a mammal, primate, livestock (e.g., sheep, cow, horse, pig), companion animal (e.g., dog, cat), or laboratory animal (e.g., mouse, rabbit, rat, guinea pig, hamster).
- livestock e.g., sheep, cow, horse, pig
- companion animal e.g., dog, cat
- laboratory animal e.g., mouse, rabbit, rat, guinea pig, hamster
- the subject is a mammal.
- the subject is human.
- the disease or condition is associated with inflammation.
- treating includes alleviation or reducing symptoms associated with a specific disorder or condition.
- the term “prevention” includes prophylaxis of the specific disorder or condition.
- the term “preventing inflammation” refers to preventing the onset or duration of the symptoms associated with inflammation.
- a compound of Formula 1, Formula 2, or any salt, solvate or stereoisomer thereof would be administered in a therapeutically effective amount.
- the term “therapeutically effective amount”, as used herein, refers to a compound being administered in an amount sufficient to alleviate or prevent to some extent one or more of the symptoms of the disorder or condition being treated. The result can be the reduction and/or alleviation of the signs, symptoms, or causes of a disease or condition, or any other desired alteration of a biological system.
- the term “therapeutically effective amount” refers to a compound of Formula 1, Formula 2, or any salt thereof, being administered in an amount sufficient to control the levels of CRP in a subject, such as by modulating or inhibiting pro-inflammatory effects of CRP.
- the compounds of the present disclosure may contain chiral (asymmetric) centers or the molecule as a whole may be chiral.
- the individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are within the scope of the present disclosure.
- halogen means fluorine, chorine, bromine, or iodine.
- alkyl whether used alone, or in compound words such as alkylaryl or alkylheteroaryl, represents a straight chain hydrocarbon (i.e. linear).
- alkyl when used alone, represents a straight chain hydrocarbon ranging in size from 4 to about 20 carbon atoms.
- the alkyl group may be a straight chain alkyl group selected from a C4- 2oalkyl or Gr-ioalkyl, such as butyl, pentyl, and hexyl groups.
- alkyl when used in compound words such as alkylaryl or alkylheteroaryl, represents a straight chain hydrocarbon ranging in size from 1 to about 20 carbon atoms.
- the alkylaryl or alkylheteroaryl group may contain a straight chain alkyl group selected from a Ci-2oalkyl, Ci-ioalkyl, C2- 2oalkyl, C2-ioalkyl, C3-ioalkyl, or C-r-ioalkyl, such as methyl, ethyl, propyl, butyl, pentyl, and hexyl groups.
- carrier and “carbocyclyl” represent a monocyclic or polycyclic ring system wherein the ring atoms are all carbon atoms, e.g., of about 3 to about 20 carbon atoms, and which may be aromatic, non-aromatic, saturated, or unsaturated, and may be substituted and/or contain fused rings.
- groups include aryl groups such as benzene, saturated groups such as cyclopentyl, or fully or partially hydrogenated phenyl, naphthyl and fluorenyl. It will be appreciated that the polycyclic ring system includes bicyclic and tricyclic ring systems.
- Heterocyclyl or “heterocyclic” whether used alone, or in compound words such as heterocyclyloxy, represents a monocyclic or polycyclic ring system wherein the ring atoms are provided by at least two different elements, typically a combination of carbon and one or more of nitrogen, sulphur and oxygen, although may include other elements for ring atoms such as selenium, boron, phosphorus, bismuth and silicon, and wherein the ring system is about 3 to about 20 atoms, and which may be aromatic such as a “heteroaryl” group, non aromatic, saturated, or unsaturated, and may be substituted and/or contain fused rings.
- the heterocyclyl may be (i) an optionally substituted cycloalkyl or cycloalkenyl group, e.g., of about 3 to about 20 ring members, which may contain one or more heteroatoms such as nitrogen, oxygen, or sulfur (examples include pyrrolidinyl, morpholino, thiomorpholino, or fully or partially hydrogenated thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, oxazinyl, thiazinyl, pyridyl and azepinyl); (ii) an optionally substituted partially saturated monocyclic or polycyclic ring system in which an aryl (or heteroaryl) ring and a heterocyclic group are fused together to form a cyclic structure (examples include chromanyl, dihydrobenzofuryl and indolinyl); or (iii) an optionally substituted fully or partially saturated polycyclic fuse
- an “aromatic” group means a cyclic group having 4m+2 p electrons, where m is an integer equal to or greater than 1.
- aromatic is used interchangeably with “aryl” to refer to an aromatic group, regardless of the valency of aromatic group.
- Aryl whether used alone, or in compound words such as arylalkyl represents: (i) an optionally substituted mono- or polycyclic aromatic carbocyclic moiety, e.g., of about 6 to about 20 carbon atoms, such as phenyl, naphthyl or fluorenyl; or, (ii) an optionally substituted partially saturated polycyclic carbocyclic aromatic ring system in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure such as a tetrahydronaphthyl, indenyl ,indanyl or fluorene ring. It will be appreciated that the polycyclic ring system includes bicyclic and tricyclic ring systems.
- heteroaryl is an aromatic group or ring containing one or more heteroatoms, such as N, O, S, Se, Si or P.
- heteroaryl is used interchangeably with “hetaryl” or “heteroaryl”
- a heteroaryl group refers to monovalent aromatic groups, bivalent aromatic groups and higher multivalency aromatic groups containing one or more heteroatoms.
- heteroaryl whether used alone, or in compound words such as alkylheteroaryl represents: (i) an optionally substituted mono- or polycyclic aromatic organic moiety, e.g., of about 5 to about 20 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen, sulfur or silicon; the heteroatom(s) interrupting a carbocyclic ring structure and having a sufficient number of delocalized p electrons to provide aromatic character, provided that the rings do not contain adjacent oxygen and/or sulfur atoms.
- an optionally substituted mono- or polycyclic aromatic organic moiety e.g., of about 5 to about 20 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen, sulfur or silicon
- the heteroatom(s) interrupting a carbocyclic ring structure and having a sufficient number of delocalized p electrons to provide aromatic character, provided that the rings do not contain adjacent oxygen and/or sulfur
- Typical 6-membered heteroaryl groups are pyrazinyl, pyridazinyl, pyrazolyl, pyridyl and pyrimidinyl. All regioisomers are contemplated, e.g., 2-pyridyl, 3-pyridyl and 4- pyridyl.
- Typical 5-membered heteroaryl rings are furyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, triazolyl, and silole.
- Bicyclic groups typically are benzo-fused ring systems derived from the heteroaryl groups named above, e.g., benzofuryl, benzimidazolyl, benzthiazolyl, indolyl, indolizinyl, isoquinolyl, quinazolinyl, quinolyl and benzothienyl; or, (ii) an optionally substituted partially saturated polycyclic heteroaryl ring system in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure such as a tetrahydroquinolyl or pyrindinyl ring.
- the polycyclic ring system includes bicyclic and tricyclic ring systems.
- alkylaryl refers to an alkyl group interrupted and/or substituted with at least one aryl group, where “alkyl” and “aryl” are as described above.
- alkylhetaryl refers to an alkyl group interrupted and/or substituted with at least one hetaryl group, where “alkyl” and “aryl” are as described above.
- the phrase “pharmaceutically acceptable salt” refers to pharmaceutically acceptable organic or inorganic salts.
- Exemplary acid addition salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., l,l'-methylene-bis-(2-hydroxy-3- naphtho
- Exemplary base addition salts include, but are not limited to, ammonium salts, alkali metal salts, for example those of potassium and sodium, alkaline earth metal salts, for example those of calcium and magnesium, and salts with organic bases, for example dicyclohexylamine, N-methyl-D-glucomine, morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl -propylamine, or a mono-, di- or trihydroxy lower alkylamine, for example mono-, di- or triethanolamine.
- organic bases for example dicyclohexylamine, N-methyl-D-glucomine, morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di-
- a pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion.
- the counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound.
- a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion.
- solvates complexes with solvents in which they are reacted or from which they are precipitated or crystallized.
- solvates a complex with water
- hydrate a complex with water
- pharmaceutically acceptable solvate refers to an association of one or more solvent molecules and a compound of the present disclosure.
- solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. It will be understood that the present disclosure encompasses solvated forms, including hydrates, of the compounds of Formula 1, Formula 2, and salts thereof.
- stereoisomer refers to compounds having the same molecular formula and sequence of bonded atoms (i.e., atom connectivity), though differ in the three- dimensional orientations of their atoms in space.
- enantiomers refers to two compounds that are stereoisomers in that they are non-superimposable mirror images of one another. Relevant stereocenters may be donated with (R)- or (S)- configuration.
- the present disclosure provides amino compounds of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
- CRP inhibitor refers to the capacity of a compound to interact with a protein target in vitro or in vivo , including in the capacity to inhibit the activity or normal function of said targets, e.g., to inhibit binding or enzymatic activity.
- a compound of Formula 1 can provide an anti-inflammatory agent, such as effective for inhibiting inflammatory effects of C-reactive protein.
- the present disclosure provides an amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
- X 1 is selected from -SO 3 H, -PO 3 H, and -CO2H;
- L 1 is selected from -CH2-CH2-, -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, -O-CH2-CH2-, -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-; and
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
- X 1 is -SO 3 H
- L 1 is selected from -CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -SO 3 H
- L 1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -SO 3 H
- L 1 is selected from -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -PO 3 H
- L 1 is selected from -CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -PO3H
- L 1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -PO 3 H
- L 1 is selected from -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -CO2H
- L 1 is selected from -CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -CO2H
- L 1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- X 1 is -CO2H
- L 1 is selected from -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-CH2-;
- R 1 and R 2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
- R 1 and R 2 for any of the above embodiments may each independently be selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci-2oalkylhetaryl.
- R 1 and R 2 for any of the above embodiments may each independently be selected from C4-ioalkyl, Ci-ioalkylaryl, and Ci-ioalkylhetaryl.
- R 1 and R 2 for any of the above embodiments may each independently be selected from C4- l oalkyl, Ci-6alkylaryl, and Ci-6alkylhetaryl.
- the alkylaryl may be as defined herein, and in one example is an alkylbenzene, such as a benzyl.
- the alkylhetaryl may be as defined herein, and in one example comprises a 5 or 6 membered monocyclic heteroaryl, such as an alkylpyridine or alkyl imidazole, for example 2, 3 or 4-methylpyridine or 2,4 or 5-methylimidazole.
- R 1 and R 2 are selected to be the same moiety or group.
- the present disclosure provides an amino compound of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, selected from the following:
- a compound of Formula 1 of the present disclosure may be prepared by various methods.
- One general method for preparing the compounds is shown below in Scheme 1:
- a secondary amine comprising R 1 and R 2 groups can be reacted with a reagent X to form a compound of Formula 1.
- X is a reactive precursor to X'-L 1 moiety, such as a haloalkyl group comprising a functional X 1 group or precursor thereof. Examples A1 to A4 in the below experimental section provide further details regarding the method according to Scheme 1.
- the compounds of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, of the present disclosure, and pharmaceutical compositions comprising the compounds or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, find use in the therapy of diseases, for example, CRP associated or dependent conditions (e.g., inflammation). Accordingly, there is provided a compound of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof as described herein, or pharmaceutical composition as described herein, for use in therapy.
- the present disclosure also provides a method of controlling C-reactive protein levels in a subject comprising administering to the subject an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples as described herein.
- the controlling of C-reactive protein levels in a subject can be by modulating or inhibiting the pro-inflammatory actions of CRP, and in particular bioactive conformations of pentameric C-reactive protein (pCRP*) or monomeric C-reactive protein (mCRP).
- the present disclosure also provides a method of preventing or treating a C-reactive protein associated disease, disorder or condition, comprising administering to a subject in need of treatment thereof an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples thereof as described herein.
- the present disclosure also provides use of a compound of Formula 1, salt, solvate or stereoisomer, or of the pharmaceutical composition, according to any aspects, embodiments or examples thereof as described herein, in the manufacture of a medicament for modulating or inhibiting C-reactive protein levels in a subject.
- Indications which can benefit from a CRP inhibitor can include diseases that are driven by a inflammatory component, especially those associated with high CRP, but not exclusively.
- diseases are the following: ischemia-reperfusion injury including myocardial infarction, stroke; organ or vascular transplants, surgery or injuries in general, burns, allogenic transplantation, atherosclerotic disease, pericarditis, miocarditis, autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, or diseases associated with inflammation driven by protein misfolding, as seen with amyloidoses, Alzheimer disease, prion diseases and age-related macular degeneration. Also diseases associated with generalized overshooting inflammation such as sepsis or COVID-19 can benefit from a CRP inhibitor.
- the compound of Formula 1 or pharmaceutical composition thereof can be administered by oral, subcutaneous or systemic route to achieve systemic exposure prior to undertaking a surgical procedure e.g. cardiac bypass surgery or heart, renal or lung transplantation that would incur ischemia/reperfusion injury of the respective organ.
- Exposure to the compound of Formula 1 or pharmaceutical composition thereof can be maintained during surgery and then during a period of post-operative recovery; wherein the period may vary from one hour, to one day, to several days or a month or longer.
- the compound of Formula 1 or pharmaceutical composition thereof can be administered to patients diagnosed with myocardial infarction, stroke, pulmonary artery embolism or other arterial embolism.
- Administration can be by systemic intraveneous route, oral, or subcutaneous to achieve acute and sustained systemic exposure.
- Period of treatment may be from one day to several days or a month or longer, to manage ongoing disease or until the disease pathology resolves.
- the compound of Formula 1 or pharmaceutical composition thereof can be administered to a patient diagnosed with a chronic inflammatory condition such as atherosclerosis, autoimmune diseases, sepsis, or COVID-19.
- Administration can be by oral, subcutaneous or systemic route to achieve periodic or sustained systemic exposure. Period of treatment may be from one day to several days or a month or longer, to manage ongoing disease or until the disease pathology resolves.
- the C-reactive protein associated disease, disorder or condition is an inflammatory disease, disorder or condition.
- the C-reactive protein associated inflammatory condition is an acute or chronic inflammatory condition.
- the acute or chronic inflammatory condition is from a bacterial, viral or fungal infection, rheumatic disease, malignancy, atherosclerosis, myocardial infarction, tissue injury, or necrosis.
- the C-reactive protein associated inflammatory disease, disorder or condition is ischemia-reperfusion injury (IRI).
- the ischemia- reperfusion injury (IRI) is from organ transplantation (e.g. renal, heart etc.), vascular surgery, acute ischemic renal injury, or delayed graft function.
- the C-reactive protein associated disease is a cardiovascular disease.
- the cardiovascular disease or condition is cardiac arrhythmia, vascular disease, myocardial infarction, stroke, congestive heart failure, myocarditis, atherosclerosis, or restenosis.
- the compound is effective for selective anti-inflammatory activity.
- the compound is not an immunosuppressant.
- the subject is immune compromised.
- the C-reactive protein associated disease, disorder or condition is a non-immune-mediated inflammatory disease (IMID).
- the C- reactive protein associated disease, disorder or condition involves sterile inflammation.
- the C-reactive protein associated disease, disorder or condition comprises one or more sterile inflammation conditions selected from cancer, gout, Alzheimer’ s disease, atherosclerosis, silicosis, asbestosis, and diabetes.
- compositions suitable for use in the methods and uses described herein comprise a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
- a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is presented as a composition.
- a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is presented as a pharmaceutical composition.
- compositions that comprise a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, with one or more pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilisers, or the like.
- the carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.
- suitable pharmaceutically acceptable carriers are known in the art and are selected based on the end use application.
- the pharmaceutically acceptable carrier may act as a diluent, dispersant or carrier for the active agents and other optional components of the composition.
- the pharmaceutically acceptable carrier may also contain materials commonly used in pharmaceutically products and can be in a wide variety of forms.
- the carrier may be water, liquid or solid emollients, silicone oils, emulsifiers, surfactants, solvents, humectants, thickeners, powders, propellants and the like.
- the composition is a pharmaceutical composition, and wherein the composition comprises a pharmaceutically acceptable excipient.
- composition may for example contain a solvent, such as water (e.g. water for injection) or a pharmaceutically acceptable organic solvent.
- a solvent such as water (e.g. water for injection) or a pharmaceutically acceptable organic solvent.
- compositions may further include diluents, buffers, citrate, trehalose, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g., benzalkonium chloride), sweeteners, antistatic agents, sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, fatty acids and fatty esters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA, zinc and other such suitable cations).
- diluents e.g., buffers, citrate, trehalose, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g
- compositions of the present disclosure may also include polymeric excipients/additives or carriers, e.g., polyvinylpyrrolidones, derivatised celluloses such as hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose, Ficolls (a polymeric sugar), hydroxyethylstarch (HES), dextrates (e.g., cyclodextrins, such as 2- h y d o x y p o p y 1 - b - c y c 1 o dc x t r i n and sulfobutylether-P-cyclodextrin), polyethylene glycols, and pectin.
- polymeric excipients/additives or carriers e.g., polyvinylpyrrolidones, derivatised celluloses such as hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropyl
- compositions according to the present disclosure are listed in “Remington: The Science & Practice of Pharmacy", 19.sup.th ed., Williams & Williams, (1995), and in the “Physician's Desk Reference", 52.sup.nd ed., Medical Economics, Montvale, N.J. (1998), and in “Handbook of Pharmaceutical Excipients", Third Ed., Ed. A. H. Kibbe, Pharmaceutical Press, 2000.
- a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, of the present disclosure may be formulated in compositions including those suitable for inhalation to the lung, by aerosol, parenteral (including intraperitoneal, intravenous, subcutaneous, or intramuscular injection) or oral administration.
- compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, into association with a carrier that constitutes one or more accessory ingredients.
- compositions are prepared by bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof into association with a liquid carrier to form a solution or a suspension, or alternatively, by bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof into association with formulation components suitable for forming a solid, optionally a particulate product, and then, if warranted, shaping the product into a desired delivery form.
- compositions for oral delivery may, for example, be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs.
- Orally administered compositions may contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation.
- sweetening agents such as fructose, aspartame or saccharin
- flavoring agents such as peppermint, oil of wintergreen, or cherry
- coloring agents such as peppermint, oil of wintergreen, or cherry
- preserving agents to provide a pharmaceutically palatable preparation.
- the compositions may be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time.
- Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such vehicles are preferably of pharmaceutical grade.
- the oral compositions described herein may contain from about 1% to about 95% of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight, and the oral compositions may be dosed 1, 2, 3, 4, 5 or more times daily.
- the oral compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight % in at least about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90.
- compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight % in less than about 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20,
- compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight % in a range provided by any two of these upper and/or lower values, for example between about 5 and 20 wt %.
- the composition is formulated for parenteral delivery.
- the composition may be a sterile, lyophilized, crystalized or amorphous composition that is suitable for reconstitution in an aqueous vehicle prior to injection.
- a composition suitable for parenteral administration conveniently comprises a sterile aqueous preparation of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, which may for example be formulated to be isotonic with the blood of the recipient.
- compositions are also provided which are suitable for administration as an aerosol, by inhalation. These formulations comprise a solution or suspension of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
- the desired formulation may be placed in a small chamber and nebulized. Nebulization may be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
- a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof of the present disclosure may for example be administered in combination with one or more additional pharmaceutically active agents.
- the composition comprises a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof as defined herein, or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable carriers, and one or more additional pharmaceutically active agents.
- the amount of active ingredient that is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the subject under treatment, including the type, species, age, weight, sex, and medical condition of the subject being treated, and the renal and hepatic function of the subject, and the particular condition, disorder or disease being treated, as well as its severity.
- An ordinary skilled physician or clinician can readily determine and prescribe the effective amount of the drug required to prevent or treat the condition, disorder or disease.
- Dosages of a compound of Formula 1, or salt, solvate or stereoisomer thereof, when used for the indicated effects, will range between, for example, about 0.01 mg per kg of body weight per day (mg/kg/day) to about 1000 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is between about 0.01 and 1000, 0.1 and 500, 0.1 and 100, 1 and 50 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is between about 0.01 and 1000 mg/kg/day.
- the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof is between about 0.1 and 100 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is greater than about 0.01, 0.1, 1, 10, 20, 50, 75, 100, 500, 1000 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is less than about 5000, 1000, 75, 50, 20, 10, 1, 0.1 mg/kg/day.
- a compound of Formula 1, or salt, solvate or stereoisomer thereof may for example be administered as a single daily dose, or otherwise the total daily dosage may be administered in divided doses of two, three, or four times daily.
- the compound of Formula 1, or salt, solvate or stereoisomer thereof may be dosed less frequently than once per day, for example once per two days, three days, four days, five days, six days, or once per week.
- DIPEA A A- D i i s o p ro p y 1 c t h y 1 a m i n c
- Table 1 provides compound numbers and nomenclature, with reference to its moelcular structure, for compounds synthesized and evaluated for CRP inhibition:
- HPLC 99.62 %.
- Method A-0.1% TFA in H2O, B: ACN; Flow Rate: 1.0 mL/min
- Chromatography was performed using an Agilent 1290 system.
- the device comprises a 1290 autosampler with a thermoelectric sample cooler and a 1290 binary pump with an integrated solvent degasser.
- Mass spectrometry was performed with an Agilent 6460 Triple Quadmpol equipped with an Agilent JetStream ESI ion source. Samples were separated on a Thermo Scientific Acclaim Organic Acid column (150 x 2.1 mm, 5 pm) at 20 °C.
- Solvents for chromatographic separation were prepared as follows: mobile phase A and mobile phase B contained 0.1 % formic acid in water and acetonitrile, respectively.
- Agilent 6460 Triple Quadrupole equipped with an Agilent JetStream ESI Source was used for mass-spectral elucidation and quantitation of Compound 1 in urine and plasma.
- Mass spectral analysis of ClOm and IS were performed in dMRM-mode. Fragmentor voltages and collision energies were optimized using Agilent MRM- Optimizer, yielding these transitions for , , , , , ,
- Ionization parameters were as follows: capillary voltage, 4300 V; fragmentor voltage, 185 V; nozzle voltage, 500 V; gas temperature, 350 °C; gas flow, 11 L/min; nebulizer pressure, 40 psi; sheath gas temperature, 350 °C; sheath gas flow, 11 L/min; cell accelerator voltage, 4 V. Fragmentation
- the fragmentation pattern for Compound 1 was elucidated.
- the ion is split by alpha-cleavage at the nitrogen to yield either m/z 123.1 (1) or m/z 130.1 (2).
- Water cleavage from the phosphate of fragment (1) leads to the formation of (3).
- PO2H is cleaved off, leaving C3H5 + m/z 41.1 (4).
- the fragment ion m/z 123.1 (1) was used.
- the other fragment ions m/z 130.2, 105.1 and 41.1 were used as qualifiers for identity.
- Agilent 6520 Quadrupole time-of-flight equipped with an Dual ESI Source was used for mass-spectral elucidation and detection of metabolites in urine and liver, spleen, kidney and muscle tissue.
- the method was considered selective when signals in blank samples were less intense than 20 % of LLOQ-samples. Blank samples were injected and analyzed in MRM-mode. Afterwards, sample matrix was spiked with 0.1 pg/mL of ClOm and 0.5 pg/mL 4-DAM and compared with peak areas of blank samples.
- the recovery of the analyte and its IS was determined by comparing peak areas of extracted plasma samples to peak areas of post-extraction spiked plasma samples. Recovery was determined at three different concentration levels resembling LLOQ, medium concentration and high concentration.
- Concentration of Compound 1 in each sample was determined by calculating peak area ratios of ClOm to IS and comparing these to the calibration curve.
- Microsomes from rat liver were purchased from Thermo Scientific, Schrö, Germany. ClOm was incubated in phosphate buffer (100 mM, pH 7.4) for 0, 60 and 120 min. Final concentrations for ClOm, NADH and microsomes were 1 mM, 20 mM and 20 mg/mL, respectively. One replicate was prepared without NADH and one replicate was prepared with heat-inactivated microsomes. For inactivation, microsomes were incubated for 30 min at 45 °C. After 0, 60 and 120 min, the reaction was stopped by adding of 400 pL acetonitrile. Samples were centrifuged to separate the microsomes from the supernatant.
- the LC-MS-method was used to elucidate the plasma concentration of ClOm over time after a single intravenous administration.
- nine male Wistar rats weighing 250 g to 350 g were purchased from Charles River Research Models and Services (Sulzfeld, Germany). Rats were anaesthetized with 1.5-2 vol % isoflurane (Abbott, Wiesbaden, Germany) and placed on a temperature-controlled surgical table to maintain a physiological body temperature during the procedure.
- two independent 26G catheters (Abbocath-T, ICU Medical B.V., VZ Houten, Netherlands) were placed in each lateral tail vein.
- rats were treated as described before with minor modifications.
- male Wistar rats (bodyweight approximately 350 g) were anesthetized as described above. After achieving adequate depth of anesthesia, rats were shaved in the caudoventral abdominal region and the skin was disinfected. The urinary bladder was exposed via a midline incision and gently externalized onto a sterile latex sheet.
- Sterile urine was drawn with insulin syringes directly from the bladder (BD Micro-FineTM + Demi, BD Medical, Le Pont de Laix Cedex, France) before intravenous application of Compound 1 and 15, 30, 45, 60 and 90 minutes after i.v. application, respectively. Freshly drawn urine was snap-frozen and kept at -80 °C until analysis.
- Rodent plasma 150 pF of EDTA-anticoagulated plasma sample was spiked with 1.5 pF IS (concentration 50 pg/mF) yielding a final concentration of 500 ng/mF of IS.
- Rodent tissue Tissue was cut into small pieces and weighed into a tube prefilled with 300 mg of glass beads. 10-fold of tissue weight of water was added. The tissue was homogenized using a PreCellFys Tissue homogenizer with 3 cycles, 15 seconds each with 6500 rpm at approximately -10 °C. Subsequently, the homogenized tissue was centrifuged at 20,000 g for 15 min at 4 °C. 500 pF of homogenized tissue was transferred and dried under vacuum. The pellet was resuspended in 150 pF of water. Afterwards, 150 pF of phosphoric acid (4 %) was added to decrease viscosity of the sample and disrupt protein binding. Samples were stirred for 15 minutes (1,000 rpm, tube shaker) and subsequently centrifuged at 20,000 g for 15 minutes at 4 °C.
- Rodent urine Samples were centrifuged at 20,000 g for 15 min at 4 °C and subsequently diluted 1:100 with water. Afterwards, 1.5 pF of IS (50 pg/mF) was added to 150 pF of diluted urine sample. Standard calibration samples were also prepared in 150 pF of 1 % murine urine sample with the same amount of of IS added (1.5 pF, 50 pg/mF, final concentration 500 ng/mF). Solid-phase-extraction
- Compound 1 was extracted from rodent plasma and tissue by solid-phase extraction (SPE). Offline-SPE was performed with a VacElut cartridge manifold.
- the weight of the rats was 250 g each. Ah animals showed normal behaviour and no abnormal clinical symptoms after Compound 1 or Compound 1-pCRP-administration.
- Table 3 shows the pharmacokinetic parameters of both animal groups.
- One treated with Compound 1 pCRP
- the other treated with Compound 1 and pCRP pCRP+
- pCRP-group demonstrated to higher biovariability and higher halftimes than the pcRP+-group.
- Calculated initial concentrations for tO and cmax were higher in the pCRP— group than in the pCRP+-group.
- Table 2 Pharmacokinetic parameters of both animal groups
- Urine samples, plasma samples as well as hepatic tissue have also been analyzed in full scan mode. EICs of several potential metabolites were extracted. Additionally, comparative analyses of pre- and post-injection urine samples have been performed with Agilent ProFinder to search for post injection urine features. For this we analyzed pre- and post- injection features and compared it with post injection urine from different time points. No post- injection specific metabolites could be detected in urine (data not shown).
- Example B3 Compound 1 inhibits pCRP* induced aggravation of renal ischemia/reperfusion injury
- pCRP human pCRP purified from human ascites was purchased from Calbiochem (Nottingham, UK) and was thoroughly dialyzed twice (1:500 v/v) against Dulbecco’s phosphate buffered saline (D-PBS) supplemented with 0.9 mM CaC12 and 0.49 mM MgC12.
- D-PBS Dulbecco’s phosphate buffered saline
- Monomeric CRP was generated by treating pCRP with 8 M urea for one hour at 37 °C and following dialysis against 25 mM Tris-HCl (pH 8.5) overnight at 4 °C as described by Biro et al. 29.
- the protein concentration was determined after each dialysis and dissociation procedure by a benchtop fluorometer (Qubit® 3.0 Fluorometer, InvitrogenTM by life technologiesTM, Carlsbad, CA, USA).
- the renal ischemia/reperfusion-injury experiments were carried out on male Wistar rats. All rats were six weeks old and body weight was between 180 and 220 g (Charles River Research Models and Services, Sulzfeld, Germany). Prior to surgery, 30 Wistar rats were randomly allocated to one of five designated groups; (1) sham-operated controls receiving flank incisions without renal clamping. Animals received i.p. vehicle D-PBS solution treatment; (2) IRI-treated rats were subjected to the surgical procedure described hereafter.
- IRI rats received i.p. 500 pi D-PBS application; (3) IRI + pCRP-treated rats: the same surgical procedure as in group (2) was performed. Animals received i.p. pCRP application in a 25 pg/ml serum concentration instead of D-PBS; (4) IRI + pCRP + Compound 1 -treated group: as in group (3) rats received i.p. pCRP application in a 25 pg/ml serum concentration. pCRP was incubated with Compound 1 (1:100 molar ratio, approximately 0.3 mg/kg) before administration; (5) IRI + 1,6-bisPC-treated group: the same surgical procedure as in group (2) was performed. Animals received i.p.
- Wistar rats were anesthetized with 1.5-2 vol% isoflurane (Abbot, Wiesbaden, Germany). Body temperature was monitored during the operation via an anal probe. Rats were shaved and disinfected and incisions were made as described by us previously. Renal pedicles were exposed and clamed for 45 minutes with non-traumatic micro vessel clips followed by 24 h reperfusion. Animals were euthanized after 24 hours of reperfusion. All rmcrosurgical procedures were conducted using a stereo microscope (Stemi 2000, Carl Zeiss).
- BUN concentration was taken as surrogate for the secretory function before and after ischemia/reperfusion injured kidneys.
- Serum probes were obtained from each rat before IRI and after 24 hours of reperfusion. Probes with macroscopic hemolysis were excluded before the reading by cobas 8000 modular analyzer (Roche, Basel) by the central laboratories of the University Medical Center, Freiburg.
- Antigen unmasking for anti-monocyte detection was done by application of pepsin solution (Digest- AllTM 3, life technologies) at room temperature for 20 min. Histomorphological changes were evaluated on Periodic acid-Schiff stained sections by quantitative measurement of tubulointerstitial injury, which was assessed by loss of tubular brush border and cast formation. The morphological assessment was scaled in five steps: with not present (0), mild (1), moderate (2), severe (3) to very severe (4).
- Transmigrated leukocytes were detected by anti-monocyte/macrophage antibody clone ED-1 (Millipore, Billerica, MA, USA) in a 1:100 dilution and renal inflammation was evaluated by counting ED-D cells in 20 randomized areas of interest of the renal cortex at x200 magnification. The number of apoptotic cells was evaluated using anti-caspase-3 antibody (Novus Biologicals, Abingdon, UK) in a 1:1,000 dilution. Sections were counterstained with Mayer’s hematoxylin. Unspecific isotype matched primary antibodies served as negative control.
- Detection of human CRP on the renal tissue sections was performed using anti-pCRP*/mCRP antibody 9C9 (1:100 dilution).
- For Western blot detection of CRP snap-frozen kidney tissue was homogenized on ice using a high-power disperser (Ultra-Turrax® IKA, Staufen, Germany) in lysis buffer (hier: Sheena tex). After centrifugation of the homogenized tissue, the supernatant was transferred, and protein concentrations were determined with BCA protein assay. GAPDH served as control.
- the protein concentration of the lysates was determined by fluorometric assay using a Qubit fluorometer. After the separation by SDS gel electrophoresis and the transfer to nitrocellulose membranes (Hybond ECL, GE Healthcare, Kunststoff, Germany), samples were probed with anti-CRP antibody clone 8 overnight at 4 °C. Monoclonal antibodies against GAPDH (abeam, Cambridge, UK) were used to ensure protein equilibration. Secondary HRP-conjugated anti-mouse antibodies (Dianova, Hamburg, Germany), enhanced chemiluminescence (ECL, GE Healthcare) were used to detect protein signals and were conserved on FUJI Medical X-Ray Film (FUJIFILM, Japan).
- IRI Ischemia/reperfusion injury
- Example B4 Compound 1 inhibits pCRP* induced aggravation of allograft rejection in a hindlimb transplantation model
- Fully genetic mismatch male rats were anesthetized, hindlimbs were shaved and thoroughly disinfected. The recipients hindlimb was amputated. The allogenic transplant was attached to the recipient’s femoral stump by an intramedullary fixation. End-to-end micro anastomoses for the femoral artery and vein were performed. All rats received postoperative subcutaneous injections of 100 pg/100 g body weight of carprofen for pain relief and 1 ml/100 g bodyweight saline solution for volume compensation. Following the surgical procedure, the rats were caged individually with monitoring by professional animal caretakers. Clinical assessment of the general condition of the animals and for hindlimb rejection was performed every eight hours by two independent surgeons.
- Rats in the pCRP group received two intraperitoneal boli of 25 pg pCRP (BD Micro-FineTM -i-Demo, 30G insulin syringes) per ml serum volume directly following to the surgical procedure and after 24 hours. Serum volume was estimated as described before 3 as a function of the body weight. Immediately after surgery, subcutaneous saline supplementation was given to avoid dehydration of the rats. In the Compound 1 treatment group (n 4, FW- ⁇ BN), rats were treated as in the pCRP group.
- rats received intravenous compound Compound 1 via a 26G catheter (Abbocath-T, ICU Medical B.V., VZ Houten, Netherlands) in the lateral tail vein every six hours for the first two postoperative days.
- Biopsies were taken on day three after transplantation of skin and muscle tissue and immunohistochemistry performed on formalin-fixed and paraffin embedded samples. After incubation with primary antibody anti-CD68 (clone EDI, 1:100) and anti-human CRP (clone 8, 1:200) for one hour at room temperature, slides were incubated with secondary antibody anti- mouse-conjugated horseradish peroxidase (Dako EnVision* System anti-mouse). HistoGreen substrate kit (Dossenheim, Germany) was used to visualize for CD68+ cells and CRP deposits, resulting in green staining.
- IRI is a major aggravating factor in organ damage and allograft rejection after allograft transplantation.
- hindlimb transplantation on fully mismatched rat strains (Lewis and Brown-Norway) as a model for acute allograft rejection of vascularized composite allografts (VCA) and clinically assessed graft survival.
- VCA vascularized composite allografts
- inactivated Streptococcus were incubated with pCRP [100 pg/ml], Compound 1 [XY pg/ml], pCRP and Compound 1 and DPBS (Control), respectively, for 30 minutes at 37° C in DPBS containing 0.9 mM calcium chloride.
- Target particles were then washed, and added to whole blood. After fixation and red blood cell lysis, cells were washed and stained, and analyzed subsequently by flow cytometry (BD LSR Fortessa Cell Analyzer).
- a protein labeling kit (597/625 nm; Sigma-Aldrich, St. Louis, MO, USA) was used. Dialyzed pCRP was labeled with Atto 594 following the manufactures protocol. Washed zymosan [10 mg/ml] was subsequently incubated with 100 pg/ml pCRP-Atto 594 conjugate in DPBS supplemented with 0.9 mM calcium chloride for 30 min at 37°C, washed and resuspended again in DPBS with CaCh and MgCh.
- Cp40 binds to C3 and C3b and prevents subsequent complement activation in human.
- the cyclic polypeptide Cp40 was added to whole blood 15 minutes before exposure to the target particles.
- CytD The fungal inhibitor of F-actin polymerization cytochalasin D (CytD) was used to prevent phagocytic cup formation.
- 20 pM CytD Cytochalasin D C2618, Sigma-Aldrich, St. Louis, MO, USA
- CytD served as control to distinguish target engulfment from simple adhesion.
- Cells were fixed to stop particle binding and phagocytosis at distinct time points using lx CellFIX dilution (BD CellFIXTM, Becton Dickinson, Franklin Lakes, NJ, USA) for 5 minutes at room temperature.
- Phagocytosis of bacteria is a crucial protective mechanism of the innate immune response and CRP mediated phagocytosis has been previously described.
- S . pneumoniae Streptococcus pneumoniae
- pCRP leads to a moderate increase in phagocytosis of S. pneumoniae in monocytes and neutrophils which is reduced by addition of Compound 1.
- Baseline phagocytosis is not affected by Compound 1, suggesting that innate immune mechanisms are not inhibited by Compound 1.
- pCRP did not increase phagocytosis of zymosan and E. coli, respectively, phagocytosis, which was also not affected by Compound 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure relates to functionalized amino compounds that can provide inhibitors of C-reactive protein (CRP). The present disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of CRP associated diseases, disorders or conditions, and particularly the treatment of inflammation associated with pro-inflammatory effects of CRP, and to related uses.
Description
C-REACTIVE PROTEIN INHIBITORS
FIELD
The present disclosure relates to functionalized amino compounds that can provide inhibitors of C-reactive protein (CRP). The present disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of CRP associated diseases, disorders or conditions, and particularly the treatment of inflammation associated with pro-inflammatory effects of CRP, and to related uses.
BACKGROUND
Inflammation arises through various diseases, disorders and conditions, and a large number of treatments are available for reducing inflammation. Ischemia/reperfusion injury (IRI) is an inflammatory response that occurs when tissue is reperfused following a prolonged period of ischemia. A primary mechanism of this IRI inflammation is often overshooting leukocyte activation, complement activation, and generation of reactive oxygen species (ROS) that lead to the release of pro-inflammatory cytokines and increased vascular permeability and consequently result in tissue damage. IRI is inevitable in many clinical situations such as organ (e.g. renal) transplantation, vascular surgery, acute ischemic renal injury, and delayed graft function. Due to the relatively limited knowledge of the pathophysiology, there are very limited treatments available for this devastating clinical condition.
The present inventors have recently identified pro-inflammatory effects of CRP associated with inflammatory response. Accordingly, there remains a need to develop safe and efficacious inihbitors of CRP for controlling associated inflammation.
It will be understood that any prior art publications referred to herein do not constitute an admission that any of these documents form part of the common general knowledge in the art, in Australia or in any other country.
SUMMARY
The present inventors have undertaken extensive research into the development of inhibitors of CRP and have surprisingly identified functionalized amino compounds effective for modulating or inhibiting CRP associated inflammatory effects.
Accordingly, in one aspect the present disclosure provides an amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
Formula 1 wherein
X1 is selected from -SO3H, -PO3H, and -CO2H;
L1 is selected from -CH2-CH2-, -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, -O-CH2-CH2-, -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-CH2-, and -O-CH2-CH2-CH2-; and
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another aspect, the present disclosure provides a pharmaceutical composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples as described herein, and a pharmaceutically acceptable excipient.
In another aspect, the present disclosure provides a method of controlling C-reactive protein levels in a subject comprising administering to the subject an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples as described herein. The controlling of C- reactive protein levels in a subject can be by modulating or inhibiting the pro-inflammatory actions of CRP, and in particular bioactive conformations of pentameric C-reactive protein (pCRP*) or monomeric C-reactive protein (mCRP).
In another aspect, the present disclosure provides a method of preventing or treating a C-reactive protein associated disease, disorder or condition, comprising administering to a subject in need of treatment thereof an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples thereof as described herein.
In another aspect, the present disclosure provides the use of a compound of Formula 1, salt, solvate or stereoisomer, or of the pharmaceutical composition, according to any aspects, embodiments or examples thereof as described herein, in the manufacture of a medicament for modulating or inhibiting C-reactive protein levels in a subject.
In some embodiments, the C-reactive protein associated disease, disorder or condition, is an ischemia-reperfusion injury including myocardial infarction, stroke, organ or vascular transplants, surgery or injuries, bums, allogenic transplantation, atherosclerotic disease, pericarditis, miocarditis, autoimmune diseases such as Crohn’s disease, ulcerative colitis,
rheumatoid arthritis, multiple sclerosis, or diseases associated with inflammation driven by protein misfolding such as amyloidoses, Alzheimer disease, prion diseases and age-related macular degeneration, or diseases associated with overshooting inflammation such as sepsis or COVID-19.
It will be appreciated that other aspects, embodiments and examples of the compounds, pharmaceutical compositions, methods, or uses, are further described herein.
DESCRIPTION General Definitions
Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, medicinal chemistry and the like).
As used herein, the term “and/or”, e.g., “X and/or Y” shall be understood to mean either "X and Y" or "X or Y" and shall be taken to provide explicit support for both meanings or for either meaning.
As used herein, the term about, unless stated to the contrary, refers to +/- 20%, more preferably +/- 10%, of the designated value.
As used herein, singular forms “a”, “an” and “the” include plural aspects, unless the context clearly indicates otherwise.
Throughout this specification, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
As used herein, the term “subject” refers to any organism susceptible to a disease or condition. For example, the subject can be a mammal, primate, livestock (e.g., sheep, cow, horse, pig), companion animal (e.g., dog, cat), or laboratory animal (e.g., mouse, rabbit, rat, guinea pig, hamster). In one example, the subject is a mammal. In one embodiment, the subject is human. In one embodiment, the disease or condition is associated with inflammation.
As used herein, the term “treating” includes alleviation or reducing symptoms associated with a specific disorder or condition.
As used herein, the term “prevention” includes prophylaxis of the specific disorder or condition. For example, as used herein, the term “preventing inflammation” refers to preventing the onset or duration of the symptoms associated with inflammation.
As would be understood by the person skilled in the art, a compound of Formula 1, Formula 2, or any salt, solvate or stereoisomer thereof would be administered in a therapeutically effective amount. The term “therapeutically effective amount”, as used herein, refers to a compound being administered in an amount sufficient to alleviate or prevent to some extent one or more of the symptoms of the disorder or condition being treated. The result can be the reduction and/or alleviation of the signs, symptoms, or causes of a disease or condition, or any other desired alteration of a biological system. In one embodiment, the term “therapeutically effective amount” refers to a compound of Formula 1, Formula 2, or any salt thereof, being administered in an amount sufficient to control the levels of CRP in a subject, such as by modulating or inhibiting pro-inflammatory effects of CRP.
The compounds of the present disclosure may contain chiral (asymmetric) centers or the molecule as a whole may be chiral. The individual stereoisomers (enantiomers and diastereoisomers) and mixtures of these are within the scope of the present disclosure.
The following definitions apply to the terms as used throughout this specification, unless otherwise limited in specific instances.
As used herein, the term “halogen” means fluorine, chorine, bromine, or iodine.
The term "alkyl" whether used alone, or in compound words such as alkylaryl or alkylheteroaryl, represents a straight chain hydrocarbon (i.e. linear). The term “alkyl”, when used alone, represents a straight chain hydrocarbon ranging in size from 4 to about 20 carbon atoms. For example, the alkyl group may be a straight chain alkyl group selected from a C4- 2oalkyl or Gr-ioalkyl, such as butyl, pentyl, and hexyl groups. The term “alkyl”, when used in compound words such as alkylaryl or alkylheteroaryl, represents a straight chain hydrocarbon ranging in size from 1 to about 20 carbon atoms. For example, the alkylaryl or alkylheteroaryl group may contain a straight chain alkyl group selected from a Ci-2oalkyl, Ci-ioalkyl, C2- 2oalkyl, C2-ioalkyl, C3-ioalkyl, or C-r-ioalkyl, such as methyl, ethyl, propyl, butyl, pentyl, and hexyl groups.
The terms "carbocyclic" and "carbocyclyl" represent a monocyclic or polycyclic ring system wherein the ring atoms are all carbon atoms, e.g., of about 3 to about 20 carbon atoms, and which may be aromatic, non-aromatic, saturated, or unsaturated, and may be substituted and/or contain fused rings. Examples of such groups include aryl groups such as benzene, saturated groups such as cyclopentyl, or fully or partially hydrogenated phenyl, naphthyl and fluorenyl. It will be appreciated that the polycyclic ring system includes bicyclic and tricyclic ring systems.
"Heterocyclyl" or "heterocyclic" whether used alone, or in compound words such as heterocyclyloxy, represents a monocyclic or polycyclic ring system wherein the ring atoms are provided by at least two different elements, typically a combination of carbon and one or more of nitrogen, sulphur and oxygen, although may include other elements for ring atoms such as selenium, boron, phosphorus, bismuth and silicon, and wherein the ring system is about 3 to about 20 atoms, and which may be aromatic such as a “heteroaryl” group, non aromatic, saturated, or unsaturated, and may be substituted and/or contain fused rings. For example, the heterocyclyl may be (i) an optionally substituted cycloalkyl or cycloalkenyl group, e.g., of about 3 to about 20 ring members, which may contain one or more heteroatoms such as nitrogen, oxygen, or sulfur (examples include pyrrolidinyl, morpholino, thiomorpholino, or fully or partially hydrogenated thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, oxazinyl, thiazinyl, pyridyl and azepinyl); (ii) an optionally substituted partially saturated monocyclic or polycyclic ring system in which an aryl (or heteroaryl) ring and a heterocyclic group are fused together to form a cyclic structure (examples include chromanyl, dihydrobenzofuryl and indolinyl); or (iii) an optionally substituted fully or partially saturated polycyclic fused ring system that has one or more bridges (examples include quinuclidinyl and dihydro- 1,4-epoxynaphthyl). It will be appreciated that the polycyclic ring system includes bicyclic and tricyclic ring systems.
As will be understood, an “aromatic” group means a cyclic group having 4m+2 p electrons, where m is an integer equal to or greater than 1. As used herein, "aromatic" is used interchangeably with "aryl" to refer to an aromatic group, regardless of the valency of aromatic group.
"Aryl" whether used alone, or in compound words such as arylalkyl represents: (i) an optionally substituted mono- or polycyclic aromatic carbocyclic moiety, e.g., of about 6 to about 20 carbon atoms, such as phenyl, naphthyl or fluorenyl; or, (ii) an optionally substituted partially saturated polycyclic carbocyclic aromatic ring system in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure such as a tetrahydronaphthyl, indenyl ,indanyl or fluorene ring. It will be appreciated that the polycyclic ring system includes bicyclic and tricyclic ring systems.
A “hetaryl”, “heteroaryl” or heteroaromatic group, is an aromatic group or ring containing one or more heteroatoms, such as N, O, S, Se, Si or P. As used herein, "heteroaromatic" is used interchangeably with “hetaryl” or "heteroaryl", and a heteroaryl group refers to monovalent aromatic groups, bivalent aromatic groups and higher multivalency aromatic groups containing one or more heteroatoms. For example, "heteroaryl"
whether used alone, or in compound words such as alkylheteroaryl represents: (i) an optionally substituted mono- or polycyclic aromatic organic moiety, e.g., of about 5 to about 20 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen, sulfur or silicon; the heteroatom(s) interrupting a carbocyclic ring structure and having a sufficient number of delocalized p electrons to provide aromatic character, provided that the rings do not contain adjacent oxygen and/or sulfur atoms. Typical 6-membered heteroaryl groups are pyrazinyl, pyridazinyl, pyrazolyl, pyridyl and pyrimidinyl. All regioisomers are contemplated, e.g., 2-pyridyl, 3-pyridyl and 4- pyridyl. Typical 5-membered heteroaryl rings are furyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, pyrrolyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl, triazolyl, and silole. All regioisomers are contemplated, e.g., 2-thienyl and 3-thienyl. Bicyclic groups typically are benzo-fused ring systems derived from the heteroaryl groups named above, e.g., benzofuryl, benzimidazolyl, benzthiazolyl, indolyl, indolizinyl, isoquinolyl, quinazolinyl, quinolyl and benzothienyl; or, (ii) an optionally substituted partially saturated polycyclic heteroaryl ring system in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure such as a tetrahydroquinolyl or pyrindinyl ring. It will be appreciated that the polycyclic ring system includes bicyclic and tricyclic ring systems.
As used herein, the term “alkylaryl” refers to an alkyl group interrupted and/or substituted with at least one aryl group, where “alkyl” and “aryl” are as described above.
As used herein, the term “alkylhetaryl” refers to an alkyl group interrupted and/or substituted with at least one hetaryl group, where “alkyl” and “aryl” are as described above.
As used herein, the phrase “pharmaceutically acceptable salt” refers to pharmaceutically acceptable organic or inorganic salts. Exemplary acid addition salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucuronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and pamoate (i.e., l,l'-methylene-bis-(2-hydroxy-3- naphthoate)) salts. Exemplary base addition salts include, but are not limited to, ammonium salts, alkali metal salts, for example those of potassium and sodium, alkaline earth metal salts, for example those of calcium and magnesium, and salts with organic bases, for example dicyclohexylamine, N-methyl-D-glucomine, morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkylamine, for example ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethyl -propylamine, or a mono-, di- or trihydroxy lower
alkylamine, for example mono-, di- or triethanolamine. A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilizes the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion.
Those skilled in the art of organic and/or medicinal chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a complex with water is known as a "hydrate". As used herein, the phrase “pharmaceutically acceptable solvate” or “solvate” refer to an association of one or more solvent molecules and a compound of the present disclosure. Examples of solvents that form pharmaceutically acceptable solvates include, but are not limited to, water, isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, and ethanolamine. It will be understood that the present disclosure encompasses solvated forms, including hydrates, of the compounds of Formula 1, Formula 2, and salts thereof.
As used herein, the term “stereoisomer” refers to compounds having the same molecular formula and sequence of bonded atoms (i.e., atom connectivity), though differ in the three- dimensional orientations of their atoms in space. As used herein, the term “enantiomers” refers to two compounds that are stereoisomers in that they are non-superimposable mirror images of one another. Relevant stereocenters may be donated with (R)- or (S)- configuration.
Those skilled in the art of organic and/or medicinal chemistry will appreciate that the compounds of Formula 1, and salts thereof, may be present in amorphous form, or in a crystalline form. It will be understood that the present disclosure encompasses all forms and polymorphs of the compounds of Formula 1, and salts thereof.
CRP Inhibitors
The present disclosure provides amino compounds of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
As used herein, the term “CRP inhibitor” refers to the capacity of a compound to interact with a protein target in vitro or in vivo , including in the capacity to inhibit the activity or normal function of said targets, e.g., to inhibit binding or enzymatic activity. In another
example, a compound of Formula 1 can provide an anti-inflammatory agent, such as effective for inhibiting inflammatory effects of C-reactive protein.
Compounds of Formula 1
In one aspect the present disclosure provides an amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
Formula 1 wherein
X1 is selected from -SO3H, -PO3H, and -CO2H;
L1 is selected from -CH2-CH2-, -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, -O-CH2-CH2-, -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-CH2-, and -O-CH2-CH2-CH2-; and
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In one embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -SO3H;
L1 is selected from -CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -SO3H;
L1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -SO3H;
L1 is selected from -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-CH2-, and -O-CH2-CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -PO3H;
L1 is selected from -CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -PO3H;
L1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -PO3H;
L1 is selected from -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-CH2-, and -O-CH2-CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -CO2H;
L1 is selected from -CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -CO2H;
L1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
In another embodiment of the amino compound of Formula 1 or a pharmaceutically acceptable salt, solvate or stereoisomer thereof:
X1 is -CO2H;
L1 is selected from -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-CH2-, and -O-CH2-CH2-CH2-;
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
R1 and R2 for any of the above embodiments may each independently be selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci-2oalkylhetaryl. R1 and R2 for any of the above embodiments may each independently be selected from C4-ioalkyl, Ci-ioalkylaryl, and Ci-ioalkylhetaryl. R1 and R2 for any of the above embodiments may each independently be selected from C4- loalkyl, Ci-6alkylaryl, and Ci-6alkylhetaryl. The alkylaryl may be as defined herein, and in one example is an alkylbenzene, such as a benzyl. The alkylhetaryl may be as defined herein, and in one example comprises a 5 or 6 membered monocyclic heteroaryl, such as an alkylpyridine or alkyl imidazole, for example 2, 3 or 4-methylpyridine or 2,4 or 5-methylimidazole. In some examples, R1 and R2 are selected to be the same moiety or group.
In another embodiment, the present disclosure provides an amino compound of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, selected from the following:
Synthesis of Compounds of Formula 1
A compound of Formula 1 of the present disclosure may be prepared by various methods. One general method for preparing the compounds is shown below in Scheme 1:
In Scheme 1 a secondary amine comprising R1 and R2 groups can be reacted with a reagent X to form a compound of Formula 1. It will be appreciated that X is a reactive precursor to X'-L1 moiety, such as a haloalkyl group comprising a functional X1 group or precursor thereof. Examples A1 to A4 in the below experimental section provide further details regarding the method according to Scheme 1.
It will be appreciated that the above groups of X1, L1, R1, and R2, may be provided according to any embodiments or examples thereof as described herein.
Therapeutic Applications
The compounds of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, of the present disclosure, and pharmaceutical compositions comprising the compounds or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, find use in the therapy of diseases, for example, CRP associated or dependent conditions (e.g., inflammation). Accordingly, there is provided a compound of Formula 1, or a pharmaceutically
acceptable salt, solvate or stereoisomer thereof as described herein, or pharmaceutical composition as described herein, for use in therapy.
A compound of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, or a pharmaceutical composition as described herein, finds use in the treatment of diseases for which modulation or inhibition of CRP is effective in the treatment thereof.
The present disclosure also provides a method of controlling C-reactive protein levels in a subject comprising administering to the subject an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples as described herein. The controlling of C-reactive protein levels in a subject can be by modulating or inhibiting the pro-inflammatory actions of CRP, and in particular bioactive conformations of pentameric C-reactive protein (pCRP*) or monomeric C-reactive protein (mCRP).
The present disclosure also provides a method of preventing or treating a C-reactive protein associated disease, disorder or condition, comprising administering to a subject in need of treatment thereof an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any aspects, embodiments or examples thereof as described herein.
The present disclosure also provides use of a compound of Formula 1, salt, solvate or stereoisomer, or of the pharmaceutical composition, according to any aspects, embodiments or examples thereof as described herein, in the manufacture of a medicament for modulating or inhibiting C-reactive protein levels in a subject.
Indications which can benefit from a CRP inhibitor can include diseases that are driven by a inflammatory component, especially those associated with high CRP, but not exclusively. Among these diseases are the following: ischemia-reperfusion injury including myocardial infarction, stroke; organ or vascular transplants, surgery or injuries in general, burns, allogenic transplantation, atherosclerotic disease, pericarditis, miocarditis, autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, or diseases associated with inflammation driven by protein misfolding, as seen with amyloidoses, Alzheimer disease, prion diseases and age-related macular degeneration. Also diseases associated with generalized overshooting inflammation such as sepsis or COVID-19 can benefit from a CRP inhibitor.
In one embodiment, the compound of Formula 1 or pharmaceutical composition thereof can be administered by oral, subcutaneous or systemic route to achieve systemic
exposure prior to undertaking a surgical procedure e.g. cardiac bypass surgery or heart, renal or lung transplantation that would incur ischemia/reperfusion injury of the respective organ. Exposure to the compound of Formula 1 or pharmaceutical composition thereof can be maintained during surgery and then during a period of post-operative recovery; wherein the period may vary from one hour, to one day, to several days or a month or longer.
In another embodiment, the compound of Formula 1 or pharmaceutical composition thereof can be administered to patients diagnosed with myocardial infarction, stroke, pulmonary artery embolism or other arterial embolism. Administration can be by systemic intraveneous route, oral, or subcutaneous to achieve acute and sustained systemic exposure. Period of treatment may be from one day to several days or a month or longer, to manage ongoing disease or until the disease pathology resolves.
In another embodiment, the compound of Formula 1 or pharmaceutical composition thereof can be administered to a patient diagnosed with a chronic inflammatory condition such as atherosclerosis, autoimmune diseases, sepsis, or COVID-19. Administration can be by oral, subcutaneous or systemic route to achieve periodic or sustained systemic exposure. Period of treatment may be from one day to several days or a month or longer, to manage ongoing disease or until the disease pathology resolves.
In some examples, the C-reactive protein associated disease, disorder or condition, is an inflammatory disease, disorder or condition. In some examples, the C-reactive protein associated inflammatory condition is an acute or chronic inflammatory condition. In some examples, the acute or chronic inflammatory condition is from a bacterial, viral or fungal infection, rheumatic disease, malignancy, atherosclerosis, myocardial infarction, tissue injury, or necrosis. In some examples, the C-reactive protein associated inflammatory disease, disorder or condition, is ischemia-reperfusion injury (IRI). In some examples, the ischemia- reperfusion injury (IRI) is from organ transplantation (e.g. renal, heart etc.), vascular surgery, acute ischemic renal injury, or delayed graft function. In some examples, the C-reactive protein associated disease is a cardiovascular disease. In some examples, the cardiovascular disease or condition is cardiac arrhythmia, vascular disease, myocardial infarction, stroke, congestive heart failure, myocarditis, atherosclerosis, or restenosis. In some examples, the compound is effective for selective anti-inflammatory activity. In some examples, the compound is not an immunosuppressant. In some examples, the subject is immune compromised. In some examples, the C-reactive protein associated disease, disorder or condition, is a non-immune-mediated inflammatory disease (IMID). In some examples, the C- reactive protein associated disease, disorder or condition, involves sterile inflammation. In
some examples, the C-reactive protein associated disease, disorder or condition, comprises one or more sterile inflammation conditions selected from cancer, gout, Alzheimer’ s disease, atherosclerosis, silicosis, asbestosis, and diabetes.
Compositions
Compositions suitable for use in the methods and uses described herein comprise a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is presented as a composition. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, is presented as a pharmaceutical composition.
The present disclosure also provides pharmaceutical compositions that comprise a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, with one or more pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilisers, or the like. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. Generally, suitable pharmaceutically acceptable carriers are known in the art and are selected based on the end use application. The pharmaceutically acceptable carrier may act as a diluent, dispersant or carrier for the active agents and other optional components of the composition. The pharmaceutically acceptable carrier may also contain materials commonly used in pharmaceutically products and can be in a wide variety of forms. For example, the carrier may be water, liquid or solid emollients, silicone oils, emulsifiers, surfactants, solvents, humectants, thickeners, powders, propellants and the like.
In some embodiments, the composition is a pharmaceutical composition, and wherein the composition comprises a pharmaceutically acceptable excipient.
The composition may for example contain a solvent, such as water (e.g. water for injection) or a pharmaceutically acceptable organic solvent.
The compositions may further include diluents, buffers, citrate, trehalose, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g., benzalkonium chloride), sweeteners, antistatic agents, sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, fatty acids and fatty esters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA, zinc and other such suitable cations).
The compositions of the present disclosure may also include polymeric excipients/additives or carriers, e.g., polyvinylpyrrolidones, derivatised celluloses such as hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose, Ficolls (a polymeric sugar), hydroxyethylstarch (HES), dextrates (e.g., cyclodextrins, such as 2- h y d o x y p o p y 1 - b - c y c 1 o dc x t r i n and sulfobutylether-P-cyclodextrin), polyethylene glycols, and pectin.
Other pharmaceutical carriers, excipients, optional ingredients and/or additives suitable for use in the compositions according to the present disclosure are listed in "Remington: The Science & Practice of Pharmacy", 19.sup.th ed., Williams & Williams, (1995), and in the "Physician's Desk Reference", 52.sup.nd ed., Medical Economics, Montvale, N.J. (1998), and in "Handbook of Pharmaceutical Excipients", Third Ed., Ed. A. H. Kibbe, Pharmaceutical Press, 2000.
A compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, of the present disclosure may be formulated in compositions including those suitable for inhalation to the lung, by aerosol, parenteral (including intraperitoneal, intravenous, subcutaneous, or intramuscular injection) or oral administration.
The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, into association with a carrier that constitutes one or more accessory ingredients.
In general, the compositions are prepared by bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof into association with a liquid carrier to form a solution or a suspension, or alternatively, by bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof into association with formulation components suitable for forming a solid, optionally a particulate product, and then, if warranted, shaping the product into a desired delivery form.
In some embodiments, the composition is formulated for oral delivery. Compositions for oral delivery may, for example, be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs. Orally administered compositions may contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in a tablet or pill form, the compositions may be coated to delay
disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such vehicles are preferably of pharmaceutical grade. The oral compositions described herein may contain from about 1% to about 95% of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight, and the oral compositions may be dosed 1, 2, 3, 4, 5 or more times daily. The oral compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight % in at least about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90. The oral compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight % in less than about 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20,
15, 10, or 5. The oral compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof by weight % in a range provided by any two of these upper and/or lower values, for example between about 5 and 20 wt %.
In some embodiments, the composition is formulated for parenteral delivery. For example, in one embodiment, the composition may be a sterile, lyophilized, crystalized or amorphous composition that is suitable for reconstitution in an aqueous vehicle prior to injection.
In one embodiment, a composition suitable for parenteral administration conveniently comprises a sterile aqueous preparation of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, which may for example be formulated to be isotonic with the blood of the recipient.
Pharmaceutical compositions are also provided which are suitable for administration as an aerosol, by inhalation. These formulations comprise a solution or suspension of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof. The desired formulation may be placed in a small chamber and nebulized. Nebulization may be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
As discussed below, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof of the present disclosure may for example be administered in combination with one or more additional pharmaceutically active agents. Thus, in some
embodiments, the composition comprises a compound of Formula I, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof as defined herein, or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable carriers, and one or more additional pharmaceutically active agents.
Dosages
The amount of active ingredient that is required to achieve a therapeutic effect will, of course, vary with the particular compound, the route of administration, the subject under treatment, including the type, species, age, weight, sex, and medical condition of the subject being treated, and the renal and hepatic function of the subject, and the particular condition, disorder or disease being treated, as well as its severity. An ordinary skilled physician or clinician can readily determine and prescribe the effective amount of the drug required to prevent or treat the condition, disorder or disease.
Dosages of a compound of Formula 1, or salt, solvate or stereoisomer thereof, when used for the indicated effects, will range between, for example, about 0.01 mg per kg of body weight per day (mg/kg/day) to about 1000 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is between about 0.01 and 1000, 0.1 and 500, 0.1 and 100, 1 and 50 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is between about 0.01 and 1000 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is between about 0.1 and 100 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is greater than about 0.01, 0.1, 1, 10, 20, 50, 75, 100, 500, 1000 mg/kg/day. In one example, the dosage of a compound of Formula 1, or salt, solvate or stereoisomer thereof, is less than about 5000, 1000, 75, 50, 20, 10, 1, 0.1 mg/kg/day.
A compound of Formula 1, or salt, solvate or stereoisomer thereof, may for example be administered as a single daily dose, or otherwise the total daily dosage may be administered in divided doses of two, three, or four times daily. In one example, the compound of Formula 1, or salt, solvate or stereoisomer thereof, may be dosed less frequently than once per day, for example once per two days, three days, four days, five days, six days, or once per week.
EXAMPLES
The present disclosure is further described by the following examples. It is to be understood that the following description is for the purpose of describing particular embodiments only and is not intended to be limiting with respect to the above description.
Abbreviations
ACN Acetonitrile
DCM Dichloromethane
DCE Dichloroethane
DIPEA A, A- D i i s o p ro p y 1 c t h y 1 a m i n c
DME Dimethyl ether
DMF Dimethylformamide
ESI Electrospray ionization
HRMS High Resolution
LCMS Liquid chromatography-mass spectrometry m/z Mass to charge ratio
NMR Nuclear magnetic resonance o.n Overnight r.t Room temperature
TFA Trifluoroacetic acid
THF T etrahy drofuran
The following Table 1 provides compound numbers and nomenclature, with reference to its moelcular structure, for compounds synthesized and evaluated for CRP inhibition:
Table 1: CRP Inhibitor Examples
Compound No. Compound Structure
1-A 1-C 1
Compound 1-C Diethyl(3-(dibutylamino)propyl)phosphonate
To a solution of Compound 1-A (dibutylamine, 0.32g, 2.5 mmol) in dimethylformamide (8 mL) was added sodium iodide (0.03 g, 0.25 mmol), potassium carbonate (1 g, 7.5 mmol) and Compound 1-B (diethyl(3-bromopropyl)phosphonate, 1.42 g, 5.5 mmol) at 0°C. The reaction mixture was heated to 100°C for 14 h. The progress of the reaction was monitored by TLC. The reaction mixture was cooled to 0°C and quenched with water (15 mL) and extracted with ethyl acetate (15 mL x 2). The combined organic layer was washed with brine (20 mL), dried over sodium sulfate and concentrated under vacuum. The residue was separated by silica gel chromatography to provide Compound 1-C (diethyl(3- (dibutylamino)propyl)phosphonate, 215 mg, 0.7 mmol, 28 % yield).
Compound 1 (3-(dibutylamino)propyl)phosphonic acid
To a solution of Compound 1-C (diethyl [3-(dibutylamino)propyl]phosphonate, 0.28 g, 0.91 mmol) in dichloromethane (25mL) was added trimethylsilyl bromide (2.79 g, 18.2 mmol, 20 eq) at 0°C. The reaction mixture was heated to 45°C for 14 h. The solvent was concentrated. Residue was dissolved in methanol (20 mL) and dichloromethane (20 mL) and then solvents were removed under vacuum. The residue was triturated under dichloromethane : hexane (1:1) (30 mL) and heated with stirring at 40 °C for 30 minutes. The solvents were decanted and the residue was dried under vacuum to provide Compound 1 (3- (dibutylamino)propyl)phosphonic acid, 0.10 g, 0.4 mmol, 44% yield).
Calc C11H26NO3P [M+H]+ = 252; found [M+H]+ = 252
Compound 2-C Diethyl(3-(dibenzylamino)propyl)phosphonate
To a solution of Compound 2- A (dibenzylamine, 0.25 g, 1.3 mmol, leq) in dimethylformamide (8 mL) was added sodium iodide (19mg, 0.13 mmol, O.leq), potassium carbonate (0.54g, 3.9mmol, 3eq) and Compound 1-B (diethyl(3-bromopropyl)phosphonate, 0.74 g, 2.9 mmol, 2.2 eq) at 0°C. Reaction mixture was heated to 100°C for 14 h. The reaction mixture was cooled to 0°C and quenched with water (15 mL) and extracted with ethyl acetate (15 mL x 2). The combined organic layer was washed with brine (20 mL), dried over sodium sulfate and concentrated under vacuum. The residue was separated by silica gel chromatography to provide Compound 2-C (diethyl(3-(dibenzylamino)propyl)phosphonate).
Compound 2 3-( Dibenzylamino )propyl-phosphonic acid
To a solution of Compound 2-C (diethyl (3-(dibenzylamino)propyl)phosphonate,
0.375 g, 1 mmol, 1 eq) in dichloromethane (25mL) was added trimethylsilyl bromide (3 g, 20 mmol, 20 eq) at 0°C. The reaction mixture was heated to 45°C for 14 h. The solvent was concentrated. The residue was dissolved in methanol (20 mL) and dichloromethane (20 mL),
and then the solvents were removed under vacuum. The residue was triturated under dichloromethane : hexane (1:1) (30 mL) and heated with stirring at 40 °C for 30 minutes. The solvents were decanted and the residue was dried under vacuum to provide Compound 2 (3- (dibenzylamino)propyl-phosphonic acid) .
'H [D2O] 7.4 (broad multiplet, 10H a); 4.30 (broad singlet, 4H, b); 3.11 (broad singlet, 2H, c); 1.96 (broad singlet, 2H, d); 1.58 (broad multiplet, 2H, e).
31P [DeMSO] 25.37 f
13C [DeMSO] 131.7, 130.3, 130.1, 129.4; 56.6; 53.0; 25.4 doublet m; 17.7.
MW: 251.39
Compound 3 3 -(Dibutylamino)propane-l -sulfonic acid)
To a stirred mixture of Compound 1-A (dibutylamine, 1.0 g, 0.0077 mol, 1 equiv.) in toluene (10 mL) was added Compound 3-B (1,2-oxathiolane 2,2-dioxide, 0.99 g, 0.0081 mol, 1.05 equiv.). The resulting reaction mixture was stirred for 3 h at 110 °C. After confirming the completion of reaction (TLC analysis: 10% MeOH/DCM; Rf~ 0.1), reaction mixture was cooled to RT and toluene was decanted. The resulting crude compound was dissolved with 10% ethyl acetate in pet ether (20 ml), stirred for 30 minutes at 50 °C and solvent was decanted. Then methanol (10 ml) was added to the residue, stirred for 30 minutes at RT. The crude compound (0.5 g) was purified by preparative HPLC (Method: 70:30, A-0.1% Formic acid in H2O, B: ACN; Flow Rate: 15 mL/min, Column: SUNFIRE C18 (30 x 250 mm, 10 pm, RT-7.47). Combined column fractions were concentrated under vacuum to yield the title Compound 3 (3 -(Dibutylamino)propane-l- sulfonic acid) as off-white gummy solid.
Yield: 0.140 g (7.30% yield).
LCMS: Mass found; (250.1; M-l)
Method: A-0.1% Formic acid in H2O, B: ACN; Flow Rate: 1.5 mL/min; -ve mode
Column: Atlantis del 8 (50 x 4.6mm, 5pm)
Rt (min): 1.36; Area% - 99.81.
HPLC: 99.54 %.
Method: A-0.1% TFA in WATER, B: ACN; Flow Rate: 1.0 mL/min Column: Atlantis dC18 (250 x 4.6mm, 5pm)
Rt (min): 7.27; Area% -99.54.
1H-NMR (400 MHz, DMSO-d6): d 9.58 (s, 1H), 3.21 (s, 2H), 3.03 (t, J = 7.60 Hz, 4H), 2.63 (t, J = 6.40 Hz, 2H), 1.96 (t, J = 6.00 Hz, 2H), 1.57 (t, J = 8.00 Hz, 4H), 1.30-1.32 (m, 4H), 0.84-0.85 (m, 6H).
Compound 4 3-(Dibenzylamino) propane-1 -sulfonic acid
To a stirred solution of Compound 2- A (dibenzylamine 1, 1.0 g, 0.0050 mol, 1 equiv.) in toluene (10 mL) was added Compound 3-B (1,2-oxathiolane 2,2-dioxide, 0.65 g, 0.0053 mol, 1.05 equiv.). The resulting reaction mixture was stirred for 3 h at 110 °C. After confirming the completion of reaction (TLC analysis: 10% MeOH/DCM; Rf~ 0.1), reaction mixture was cooled to RT and toluene was decanted. The resulting crude was dissolved with 10% ethyl acetate in pet ether (20 ml), stirred for 30 minutes at 50 °C and solvent was decanted. Then, methanol (10 ml) was added to the residue and stirred for 30 minutes at RT. The precipitated solid was collected by filtration and dried under reduced pressure to afford the title Compound 4 (3-(Dibenzylamino) propane- 1- sulfonic acid) as off-white solid.
Yield: 0.8 g (50% yield).
LCMS: Mass found; (318.1; M-l)
Method: A-0.1% Formic acid in H2O, B: ACN; Flow Rate: 1.5 mL/min; -ve mode Column: Atlantis dC18 (50 x 4.6mm, 5pm)
Rt (min): 1.82; Area% - 99.62.
HPLC: 99.62 %.
Method: A-0.1% TFA in H2O, B: ACN; Flow Rate: 1.0 mL/min Column: Atlantis dc-18 (250 x 4.6mm, 5mhi)
Rt (min): 8.63; Area% -99.62.
1H-NMR (400 MHz, DMSO-d6): d 10.79 (s, 1H), 7.47 (t, J = 2.72 Hz, 10H), 4.41 (dd, J = 4.64, 13.16 Hz, 2H), 4.19 (dd, J = 4.68, 13.14 Hz, 2H), 3.19 (d, J = 5.08 Hz, 2H),
2.57 (d, J = 5.64 Hz, 2H), 2.16 (d, J = 5.08 Hz, 2H).
B. Biological Evaluation of CRP Inhibitors
Example Bl: Liver microsome stability of Compound 1
Analytical Instrumentation
Chromatography was performed using an Agilent 1290 system. The device comprises a 1290 autosampler with a thermoelectric sample cooler and a 1290 binary pump with an integrated solvent degasser. Mass spectrometry was performed with an Agilent 6460 Triple Quadmpol equipped with an Agilent JetStream ESI ion source. Samples were separated on a Thermo Scientific Acclaim Organic Acid column (150 x 2.1 mm, 5 pm) at 20 °C. Solvents for chromatographic separation were prepared as follows: mobile phase A and mobile phase B contained 0.1 % formic acid in water and acetonitrile, respectively. Separation of analytes from matrix components was achieved by gradient elution: 0-3 min, 2 % B; 3-10 min, 40 % B; 14.5 min, 100 % B; 17 min, 100 % B; 17.1 min, 2 % B; 21 min, 2 % B with a flow rate of 0.6 mL/min.
Mass spectrometric conditions
Agilent 6460 Triple Quadrupole equipped with an Agilent JetStream ESI Source was used for mass-spectral elucidation and quantitation of Compound 1 in urine and plasma. Mass spectral analysis of ClOm and IS were performed in dMRM-mode. Fragmentor voltages and collision energies were optimized using Agilent MRM- Optimizer, yielding these transitions for
, , , , , ,
142.2, 18 V; 4-DAM, 216.1
130.2, 14 V; 4-DAM, 216.1
86.6, 26 V. Ionization parameters were as follows: capillary voltage, 4300 V; fragmentor voltage, 185 V; nozzle voltage, 500 V; gas temperature, 350 °C; gas flow, 11 L/min; nebulizer pressure, 40 psi; sheath gas temperature, 350 °C; sheath gas flow, 11 L/min; cell accelerator voltage, 4 V.
Fragmentation
The fragmentation pattern for Compound 1 was elucidated. In the first fragmentation step, the ion is split by alpha-cleavage at the nitrogen to yield either m/z 123.1 (1) or m/z 130.1 (2). Water cleavage from the phosphate of fragment (1) leads to the formation of (3). In a last alpha-cleavage PO2H is cleaved off, leaving C3H5+ m/z 41.1 (4). For quantification the fragment ion m/z 123.1 (1) was used. The other fragment ions m/z 130.2, 105.1 and 41.1 were used as qualifiers for identity.
Untargeted analysis
Agilent 6520 Quadrupole time-of-flight equipped with an Dual ESI Source was used for mass-spectral elucidation and detection of metabolites in urine and liver, spleen, kidney and muscle tissue.
Mass spectral analysis of Compound 1 and its potential metabolites was performed in full scan mode. Ionization parameters were as follows: capillary voltage, +4300 V; fragmentor voltage, 185 V; gas temperature, 350 °C; gas flow, 11 L/min; nebulizer pressure, 40 psi; scan range, 100 - 1000 m/z. Reference masses were m/z 121.050873 and 922.009798 for Purine and HP-0921, respectively (Sum formula of purine: C5H4N4[+H+], m/z = 121.050873; Sum formula of HP-0921: C18H18N306F26P3[+H+], m/z = 922.009798).
Selectivity
The method was considered selective when signals in blank samples were less intense than 20 % of LLOQ-samples. Blank samples were injected and analyzed in MRM-mode. Afterwards, sample matrix was spiked with 0.1 pg/mL of ClOm and 0.5 pg/mL 4-DAM and compared with peak areas of blank samples.
Recovery
The recovery of the analyte and its IS was determined by comparing peak areas of extracted plasma samples to peak areas of post-extraction spiked plasma samples. Recovery was determined at three different concentration levels resembling LLOQ, medium concentration and high concentration.
Linearity of calibration curves
Concentration of Compound 1 in each sample was determined by calculating peak area ratios of ClOm to IS and comparing these to the calibration curve. Seven calibration standards
(10, 5, 2.5, 1, 0.6, 0.3 and 0.1 mg/mL) and three QC-standards (10, 1 and 0.1 mg/mL) were prepared in an adequate matrix (human plasma or murine urine diluted 1:100). Calibrations were performed at 10, 5, 2.5, 1, 0.6, 0.3 and 0.1 pg/mL and at 5, 3.5, 2, 1, 0.6, 0.3 and 0.1 pg/mL for plasma and urine, respectively. Quality controls were chosen at ULOQ, M and LLOQ. IS was always added to a concentration of 0.5 pg/mL. Calculation of concentrations was performed with Agilent Quantitative Analysis B.07.01 SP2. The created calibration function y = m * x + c was weighed 1/x2.
Linearity of quantification
For plasma calibration curves Compound 1 signal intensities showed good linearity over the range of 0.1-10 pg/mL. The same was true for calibration curves in urine over the range of 0.1-5 pg/mL. An exemplary function for a calibration curve from plasma is y = 1.1928 * x + 0.16985. Y depicts the ratio of peak-area of analyte of interest to peak-area of the IS. x represents the calculated concentration of the analyte. The calibration function was weighed 1/ x 2. Calculations were run by Agilent Quantitative Analysis B.07.01.
Precision, Accuracy, LLOQ
Accuracy and precision were determined by analyzing six replicates each for three different concentrations across the linear range for plasma and urine matrix: At LLOQ (0.1 pg/mL), medium concentration (1 pg/mL) as well as at the maximum (Plasma: 10 pg/mL; Urine: 5 pg/mL). Accuracy was considered acceptable for deviations within ±15 % (±20 % at LLOQ). Precision was considered acceptable for coefficients of variation <15 % (<20 % at LLOQ).
Results for all precision and accuracy values are depicted in Table 2. All coefficients of variation were within ±15 % (±20 % at LLOQ). Accuracy of all calibration standards was between 85 % and 115 % (between 80 % and 120 % at LLOQ).
Table 1. Precision and accuracy for Compound 1 determination in Plasma and Urine.
Matrix Plasma Urine
LLOQ 97.3 % 98.1 %
Accuracy Mid 112.7 % 108.8 % High 87.8 % 91.0 % LLOQ 4.92 % 3.81 %
Precision Mid 0.87 % 3.43 % High 3.52 % 2.1 %
Microsome incubation
Prior to tissue analysis, we performed microsomal incubations with Compound 1 to elucidate any potential metabolites. Microsomes from rat liver were purchased from Thermo Scientific, Schwerte, Germany. ClOm was incubated in phosphate buffer (100 mM, pH 7.4) for 0, 60 and 120 min. Final concentrations for ClOm, NADH and microsomes were 1 mM, 20 mM and 20 mg/mL, respectively. One replicate was prepared without NADH and one replicate was prepared with heat-inactivated microsomes. For inactivation, microsomes were incubated for 30 min at 45 °C. After 0, 60 and 120 min, the reaction was stopped by adding of 400 pL acetonitrile. Samples were centrifuged to separate the microsomes from the supernatant.
Example B2: Pharmacokinetic study of Compound 1
Pharmacokinetic study in rats
The following animal studies were carried out according to the recommendations of the animal ethic committee of the University of Freiburg Medical Center, Germany.
As described above, the LC-MS-method was used to elucidate the plasma concentration of ClOm over time after a single intravenous administration. For the pharmacokinetic studies, nine male Wistar rats weighing 250 g to 350 g were purchased from Charles River Research Models and Services (Sulzfeld, Germany). Rats were anaesthetized with 1.5-2 vol % isoflurane (Abbott, Wiesbaden, Germany) and placed on a temperature-controlled surgical table to maintain a physiological body temperature during the procedure. To ensure interference-free blood sampling, two independent 26G catheters (Abbocath-T, ICU Medical B.V., VZ Houten, Netherlands) were placed in each lateral tail vein. Blood was taken prior to the injection of 47- 65 pg ClOm (approximately 5.4 pg per mL plasma which equals approximately 100-fold the amount of pCRP during inflammation) and at eight given time points (1, 5, 10, 15, 30, 45, 60 and 90 minutes after bolus administration). Samples were collected in EDTA-coated tubes
(1.6 mg EDTA/ml, Sarstedt micro tubes, Niimbrecht, Germany). Plasma was separated from the cellular phase by centrifugation for 10 minutes at 2,000 g using a refrigerated table-top centrifuge at 4 °C. The resulting supernatant was snap-frozen and stored at -80 °C until sample preparation with solid-phase extraction.
For the renal excretion assay, rats were treated as described before with minor modifications. In brief, male Wistar rats (bodyweight approximately 350 g) were anesthetized as described above. After achieving adequate depth of anesthesia, rats were shaved in the caudoventral abdominal region and the skin was disinfected. The urinary bladder was exposed via a midline incision and gently externalized onto a sterile latex sheet. Sterile urine was drawn with insulin syringes directly from the bladder (BD Micro-Fine™ + Demi, BD Medical, Le Pont de Laix Cedex, France) before intravenous application of Compound 1 and 15, 30, 45, 60 and 90 minutes after i.v. application, respectively. Freshly drawn urine was snap-frozen and kept at -80 °C until analysis.
Pharmacokinetic parameters were calculated using PKSolver add-in for Microsoft
Excel.
Sample preparation
Rodent plasma: 150 pF of EDTA-anticoagulated plasma sample was spiked with 1.5 pF IS (concentration 50 pg/mF) yielding a final concentration of 500 ng/mF of IS.
Rodent tissue: Tissue was cut into small pieces and weighed into a tube prefilled with 300 mg of glass beads. 10-fold of tissue weight of water was added. The tissue was homogenized using a PreCellFys Tissue homogenizer with 3 cycles, 15 seconds each with 6500 rpm at approximately -10 °C. Subsequently, the homogenized tissue was centrifuged at 20,000 g for 15 min at 4 °C. 500 pF of homogenized tissue was transferred and dried under vacuum. The pellet was resuspended in 150 pF of water. Afterwards, 150 pF of phosphoric acid (4 %) was added to decrease viscosity of the sample and disrupt protein binding. Samples were stirred for 15 minutes (1,000 rpm, tube shaker) and subsequently centrifuged at 20,000 g for 15 minutes at 4 °C.
Rodent urine: Samples were centrifuged at 20,000 g for 15 min at 4 °C and subsequently diluted 1:100 with water. Afterwards, 1.5 pF of IS (50 pg/mF) was added to 150 pF of diluted urine sample. Standard calibration samples were also prepared in 150 pF of 1 % murine urine sample with the same amount of of IS added (1.5 pF, 50 pg/mF, final concentration 500 ng/mF).
Solid-phase-extraction
Compound 1 was extracted from rodent plasma and tissue by solid-phase extraction (SPE). Offline-SPE was performed with a VacElut cartridge manifold.
SPE-columns (Waters, Oasis MCX, 1 mL, 30 meq) were equilibrated with 1 mL methanol and 1 mL water. Samples were loaded on the column and washed with 1 mL methanol and 1 mL HC1. After elution of 1 mL HC1, vacuum (0.7 bar) was applied and the cartridges were let run dry. Elution of ClOm and its metabolites was achieved using 2 x 750 pL methanol with 5 % Ntb. The eluate was vacuum dried and resuspended in 150 pL of 2 % ACN with 0.1 % formic acid (starting chromatographic condition).
Results: Pharmacokinetics
In one group (pCRP ) consisting of 3 rats, 47 pg Compound 1 was injected to each animal. The other group (3 rats; pCRP+) received the same amount of compound plus pCRP (25 pg/mL). The chosen pCRP-concentration approximates to pCRP levels during inflammation. After administration of Compound 1 and pCRP, blood samples from both groups (pCRP+ = Compound 1 + pCRP; pCRP = ClOm) were drawn after 1, 5, 10, 15, 30, 45, 60 and 90 minutes. After analysis, the average plasma concentration for each timepoint and cmax were calculated (cmaxpCRP- = 864.4 ± 172.3 ng mL 1 as well as cmaxPcRP+ = 542.0 ± 131.1 ng mL 1; for graphs see figure 7 a-c). Biovariability in the pCRP+- group appeared to be higher than in pCRP -group. This might be because Compound 1 has bound to pCRP and, thus, is not freely available for excretion. Independently of pCRP-administration and most likely due to its polar nature, Compound 1 was excreted at a high rate: After 30 minutes, most of the compound was eliminated from plasma (tl/2PcRP- = 26.9 ± 1.3 min; tl/2PcRP+ = 134.1 ± 57.7 min). Their standard deviations was determined for each time point and both groups. Table 3 comprises ah pharmacokinetic parameters. Additional administration of pCRP yielded an initially higher Compound 1 concentration, thus lowering drug-elimination halftimes.
The weight of the rats was 250 g each. Ah animals showed normal behaviour and no abnormal clinical symptoms after Compound 1 or Compound 1-pCRP-administration.
Table 3 below shows the pharmacokinetic parameters of both animal groups. One treated with Compound 1 (pCRP) and the other treated with Compound 1 and pCRP (pCRP+). pCRP-group demonstrated to higher biovariability and higher halftimes than the pcRP+-group. Calculated initial concentrations for tO and cmax were higher in the pCRP— group than in the pCRP+-group.
Table 2. Pharmacokinetic parameters of both animal groups
Pharmacokinetic Compound 1-injection
Parameters pCRP pCRP+ Animal # 1.1 - 1.3 1.4 - 1.6 tl/2 / min 26.9 + 1.3 134.1 + 57.7
Cmax / ng mL 1 864.4 + 172.3 542.0 + 131.1
CO / ng mL 1 997.2 + 220.4 765.4 + 244.3
AUC 0-t / ng min mL 15,167.4 + 21.129.1 + 2,674.3
1 1,057.
AUC 0-co / ng min 16,550 + 45,203.3 + mL 1 1,126.5 11,371.3
Results: Urine and tissue analysis
Urine samples, plasma samples as well as hepatic tissue have also been analyzed in full scan mode. EICs of several potential metabolites were extracted. Additionally, comparative analyses of pre- and post-injection urine samples have been performed with Agilent ProFinder to search for post injection urine features. For this we analyzed pre- and post- injection features and compared it with post injection urine from different time points. No post- injection specific metabolites could be detected in urine (data not shown).
Even though renal elimination appeared to top off at 80 %, we could not determine any metabolites. Collecting urine from later points in time such as 120 or 180 min might be helpful. We also analyzed hepatic, kidney, spleen and muscle tissue which either contained concentrations of Compound 1 below the LLOQ or no Compound 1 at all.
Results: Urinary samples
Three additional animals weighing 350 g each were injected 68, 108 and 108 pg of Compound 1 of which 68 pg approximate to 100 fold of pCRP during inflammation. The bladder of each animal was emptied prior to injection. After 15, 30, 45, 60 and 90 minutes, the bladder was emptied again and its volume and Compound 1-concentration were determined. This analysis revealed that most of the compound (60-80 %) was renally eliminated after 45 to 90 minutes without any metabolism (Figure 8b). The data also supports the assumption of higher elimination rates in urine with higher i.v. doses. Elimination rates for animal #1 and #2.1 are similar, even though their initial dose was substantially different. Animal #2.11 showed lower initial speed of elimination. Less than 10 % were eliminated after
15 minutes via urine. After 30 minutes though, approximately 50 % were excreted as with the rest of the animals.
Example B3: Compound 1 inhibits pCRP* induced aggravation of renal ischemia/reperfusion injury
Reagents and antibodies
Preparation of human pCRP was performed as described before by our group 12. In brief, pCRP purified from human ascites was purchased from Calbiochem (Nottingham, UK) and was thoroughly dialyzed twice (1:500 v/v) against Dulbecco’s phosphate buffered saline (D-PBS) supplemented with 0.9 mM CaC12 and 0.49 mM MgC12. Monomeric CRP was generated by treating pCRP with 8 M urea for one hour at 37 °C and following dialysis against 25 mM Tris-HCl (pH 8.5) overnight at 4 °C as described by Biro et al. 29. The protein concentration was determined after each dialysis and dissociation procedure by a benchtop fluorometer (Qubit® 3.0 Fluorometer, Invitrogen™ by life technologies™, Carlsbad, CA, USA).
Renal IRI
The renal ischemia/reperfusion-injury experiments were carried out on male Wistar rats. All rats were six weeks old and body weight was between 180 and 220 g (Charles River Research Models and Services, Sulzfeld, Germany). Prior to surgery, 30 Wistar rats were randomly allocated to one of five designated groups; (1) sham-operated controls receiving flank incisions without renal clamping. Animals received i.p. vehicle D-PBS solution treatment; (2) IRI-treated rats were subjected to the surgical procedure described hereafter.
IRI rats received i.p. 500 pi D-PBS application; (3) IRI + pCRP-treated rats: the same surgical procedure as in group (2) was performed. Animals received i.p. pCRP application in a 25 pg/ml serum concentration instead of D-PBS; (4) IRI + pCRP + Compound 1 -treated group: as in group (3) rats received i.p. pCRP application in a 25 pg/ml serum concentration. pCRP was incubated with Compound 1 (1:100 molar ratio, approximately 0.3 mg/kg) before administration; (5) IRI + 1,6-bisPC-treated group: the same surgical procedure as in group (2) was performed. Animals received i.p. 1,6-bisPC application only (n = 6 per group). Wistar rats were anesthetized with 1.5-2 vol% isoflurane (Abbot, Wiesbaden, Germany). Body temperature was monitored during the operation via an anal probe. Rats were shaved and disinfected and incisions were made as described by us previously. Renal pedicles were
exposed and clamed for 45 minutes with non-traumatic micro vessel clips followed by 24 h reperfusion. Animals were euthanized after 24 hours of reperfusion. All rmcrosurgical procedures were conducted using a stereo microscope (Stemi 2000, Carl Zeiss).
Excretory function of I/R-injured kidneys assessed by Blood Urea Nitrogen (BUN)
BUN concentration was taken as surrogate for the secretory function before and after ischemia/reperfusion injured kidneys. Serum probes were obtained from each rat before IRI and after 24 hours of reperfusion. Probes with macroscopic hemolysis were excluded before the reading by cobas 8000 modular analyzer (Roche, Basel) by the central laboratories of the University Medical Center, Freiburg.
Immunostaining and histomorphological evaluation
Immunohistochemistry and histomorphological evaluation of the renal tissue was performed on formalin-fixed paraffin-embedded renal tissue sections (5 pm thick serial sections). Previously, both kidneys were flushed till bloodlessness with D-PBS followed by 4% formalin for fixation. Kidneys were then excised and examined in blinded fashion by two researchers using a Zeiss microscope (Carl Zeiss Microscopy Axio Imager.M2, Germany). Staining was performed as described previously. Paraffin-embedded sections were de- paraffinized in xylol, rehydrated, and boiled for 20 min in concentrated citric acid (pH 6.0). Antigen unmasking for anti-monocyte detection was done by application of pepsin solution (Digest- All™ 3, life technologies) at room temperature for 20 min. Histomorphological changes were evaluated on Periodic acid-Schiff stained sections by quantitative measurement of tubulointerstitial injury, which was assessed by loss of tubular brush border and cast formation. The morphological assessment was scaled in five steps: with not present (0), mild (1), moderate (2), severe (3) to very severe (4). Transmigrated leukocytes were detected by anti-monocyte/macrophage antibody clone ED-1 (Millipore, Billerica, MA, USA) in a 1:100 dilution and renal inflammation was evaluated by counting ED-D cells in 20 randomized areas of interest of the renal cortex at x200 magnification. The number of apoptotic cells was evaluated using anti-caspase-3 antibody (Novus Biologicals, Abingdon, UK) in a 1:1,000 dilution. Sections were counterstained with Mayer’s hematoxylin. Unspecific isotype matched primary antibodies served as negative control. Detection of human CRP on the renal tissue sections was performed using anti-pCRP*/mCRP antibody 9C9 (1:100 dilution). For Western blot detection of CRP snap-frozen kidney tissue was homogenized on ice using a high-power disperser (Ultra-Turrax® IKA, Staufen, Germany) in lysis buffer (hier: Sheena fragen). After
centrifugation of the homogenized tissue, the supernatant was transferred, and protein concentrations were determined with BCA protein assay. GAPDH served as control.
Western blot analysis
SDS-PAGE and subsequent Western blot analysis was conducted for CRP binding to activated human platelets as described previously. Briefly, human platelets were isolated and washed from citrate-anticoagulated whole blood by differential centrifugation in Sequestrene™ buffer. pCRP [100 pg/rnl] was incubated with ADP-activated platelets and Compound 1 in different concentrations [10 mM and 100 mM]. Calcium-depleted platelets served as a control. Platelets were then washed three times in DPBS supplemented with Ca++ and Mg++. Platelets were pelleted and homogenized on ice by applying shear-stress followed by freeze-and-thaw cycles in liquid nitrogen). The protein concentration of the lysates was determined by fluorometric assay using a Qubit fluorometer. After the separation by SDS gel electrophoresis and the transfer to nitrocellulose membranes (Hybond ECL, GE Healthcare, Munich, Germany), samples were probed with anti-CRP antibody clone 8 overnight at 4 °C. Monoclonal antibodies against GAPDH (abeam, Cambridge, UK) were used to ensure protein equilibration. Secondary HRP-conjugated anti-mouse antibodies (Dianova, Hamburg, Germany), enhanced chemiluminescence (ECL, GE Healthcare) were used to detect protein signals and were conserved on FUJI Medical X-Ray Film (FUJIFILM, Japan).
Results
Ischemia/reperfusion injury (IRI) represents the prototypic sterile inflammation in which exacerbated immune response leads to unwanted tissue damage and therefore represents the ideal scenario to test the therapeutic potential of Compound 1. IRI associated tissue damage is induced by the conformational change of circulating pCRP to pCRP*. To evaluate the in vivo feasibility of CRP-blocking and the relevance of our findings, we used a previously described IRI-induced acute renal injury model in rats.
After IRI rat kidneys were examined for CRP deposits by immunohistochemistry and Western blotting. Staining for CRP using the conformation- specific anti-pCRP* antibody 9C9 demonstrates deposition of CRP specifically localized to the IRI-disturbed renal tissue. After intravenous administration of C10M CRP deposition could not be detected in the tissue. This was further confirmed by Western blots of tissue lysates separated by SDS-PAGE. The functional relevance of this finding was assessed by immunohistochemistry detecting CD68+ monocytic cell infiltration in renal tissue and PAS staining of renal tissue. In these assays,
administration of pCRP leads to significant increase of IRI associated inflammatory cell infiltration and tissue injury that can be blunted by the administration of Compound 1. This aggravation of IRI significantly affects the excretory renal function as analyzed by blood urea levels.
Example B4: Compound 1 inhibits pCRP* induced aggravation of allograft rejection in a hindlimb transplantation model
Hindlimb allotransplantation
Fully genetic mismatch male rats were anesthetized, hindlimbs were shaved and thoroughly disinfected. The recipients hindlimb was amputated. The allogenic transplant was attached to the recipient’s femoral stump by an intramedullary fixation. End-to-end micro anastomoses for the femoral artery and vein were performed. All rats received postoperative subcutaneous injections of 100 pg/100 g body weight of carprofen for pain relief and 1 ml/100 g bodyweight saline solution for volume compensation. Following the surgical procedure, the rats were caged individually with monitoring by professional animal caretakers. Clinical assessment of the general condition of the animals and for hindlimb rejection was performed every eight hours by two independent surgeons. According to an established clinical classification for allograft rejection, hindlimb transplants were graded from 0 (no clinical signs of rejection), 1 (edema), 2 (erythema), and 3 (epidermolysis and desquamation) to 4 (necrosis). Overall survival and rejection of the VCA were assessed clinically and histologically. Four experimental groups were included in this study (n=4). In the control group (n=4, FW-^BN), Brown-Norway recipient rats received intraperitoneal DPBS administration. Rats in the pCRP group received two intraperitoneal boli of 25 pg pCRP (BD Micro-Fine™ -i-Demo, 30G insulin syringes) per ml serum volume directly following to the surgical procedure and after 24 hours. Serum volume was estimated as described before 3 as a function of the body weight. Immediately after surgery, subcutaneous saline supplementation was given to avoid dehydration of the rats. In the Compound 1 treatment group (n=4, FW-^BN), rats were treated as in the pCRP group. Additionally, rats received intravenous compound Compound 1 via a 26G catheter (Abbocath-T, ICU Medical B.V., VZ Houten, Netherlands) in the lateral tail vein every six hours for the first two postoperative days. Biopsies were taken on day three after transplantation of skin and muscle tissue and immunohistochemistry performed on formalin-fixed and paraffin embedded samples. After incubation with primary antibody anti-CD68 (clone EDI, 1:100) and anti-human CRP (clone
8, 1:200) for one hour at room temperature, slides were incubated with secondary antibody anti- mouse-conjugated horseradish peroxidase (Dako EnVision* System anti-mouse). HistoGreen substrate kit (Dossenheim, Germany) was used to visualize for CD68+ cells and CRP deposits, resulting in green staining.
Results
IRI is a major aggravating factor in organ damage and allograft rejection after allograft transplantation. To confirm the in vivo relevance of our findings, we performed hindlimb transplantation on fully mismatched rat strains (Lewis and Brown-Norway) as a model for acute allograft rejection of vascularized composite allografts (VCA) and clinically assessed graft survival. We found human CRP to strongly promote the diapedesis of monocytes and tissue degradation, and thereby accelerate VCA-graft loss significantly compared to a transplanted control group (control vs CRP, 8.0 ± 0.5 vs 5.0 ± 0.5 days). Most importantly, premature graft loss driven by pCRP was prevented by intravenous Compound 1 application during the first two days after transplantation. Compound 1 effects are attributable to pCRP inhibition as without extrinsic CRP application Compound 1 did not show protective effects. Transplanted rat hindlimbs showed significant clinical signs of rejection (edema, erythema, and blistering) on day three after transplantation after CRP administration, that were not present in the control group and when CRP effects were blocked with Compound 1.
Skin and muscle biopsies were taken at day 3 and were analyzed histologically. Monocyte infiltration was detected by immunofluorescence, which revealed significantly more monocyte infiltrates in VCA-tissue of rats treated with CRP compared to control rats (supplemental data). To investigate whether these exacerbating effects were specific for CRP C10M was used to block CRP. In rats treated with both CRP and Compound 1 no CRP deposits were detected. We found the number of transmigrated CD68+ cells to be reduced to control levels when Compound 1 was administered in the CRP group. These results indicate that compound Compound 1 inhibits the CRP-dependent activation and transmigration and thereby abrogates the CRP-mediated local exacerbation in VCA.
Example B5: Compound 1 does not suppress CRP- independent host defense against pathogens
Whole blood assay for opsono-phagocytosis
To assess the influence of the inhibitory compound Compound 1 on the CRP-mediated phagocytosis of pathogens, heat-inactivated Streptococcus pneumoniae serotype 27 were labeled with fluorescein-isothiocyanate (FITC) as described elsewhere. Heparinized whole blood was freshly taken from healthy human volunteers and processed within thirty minutes. For phagocytosis time course experiments, opsonized Streptococcus-FITC was incubated for 5, 10, 15 and 20 minutes with fresh whole blood at 37° C, 5 % CO2. Opsonization of target particles was done as described before with minor modifications. Briefly, inactivated Streptococcus were incubated with pCRP [100 pg/ml], Compound 1 [XY pg/ml], pCRP and Compound 1 and DPBS (Control), respectively, for 30 minutes at 37° C in DPBS containing 0.9 mM calcium chloride. Target particles were then washed, and added to whole blood. After fixation and red blood cell lysis, cells were washed and stained, and analyzed subsequently by flow cytometry (BD LSR Fortessa Cell Analyzer).
Opsonization of zymosan by pCRP
For binding studies of human pCRP to zymosan a protein labeling kit (597/625 nm; Sigma-Aldrich, St. Louis, MO, USA) was used. Dialyzed pCRP was labeled with Atto 594 following the manufactures protocol. Washed zymosan [10 mg/ml] was subsequently incubated with 100 pg/ml pCRP-Atto 594 conjugate in DPBS supplemented with 0.9 mM calcium chloride for 30 min at 37°C, washed and resuspended again in DPBS with CaCh and MgCh. Calcium dependent binding of the pCRP-Atto 594 conjugate was tested using ten millimoles of EDTA during the incubation and served as control as described before. Were indicated, complement activation was inhibited using the second generation Compstatin-analogon Cp40 (D-Tyr-Ile-[Cys-Val-lMeTrp-Gln-Asp-Trp-Sar-Ala-His-Arg-Cys]-meIle). Cp40 binds to C3 and C3b and prevents subsequent complement activation in human. The cyclic polypeptide Cp40 was added to whole blood 15 minutes before exposure to the target particles. The fungal inhibitor of F-actin polymerization cytochalasin D (CytD) was used to prevent phagocytic cup formation. 20 pM CytD (Cytochalasin D C2618, Sigma-Aldrich, St. Louis, MO, USA) served as control to distinguish target engulfment from simple adhesion. Cells were fixed to stop particle binding and phagocytosis at distinct time points using lx CellFIX dilution (BD CellFIX™, Becton Dickinson, Franklin Lakes, NJ, USA) for 5 minutes at room temperature.
Results
Phagocytosis of bacteria is a crucial protective mechanism of the innate immune response and CRP mediated phagocytosis has been previously described. In order to demonstrate that phagocytosis of Streptococcus pneumoniae ( S . pneumoniae ) is not abrogated by Compound 1 we performed a flow-cytometry based phagocytosis assay. pCRP leads to a moderate increase in phagocytosis of S. pneumoniae in monocytes and neutrophils which is reduced by addition of Compound 1. Baseline phagocytosis is not affected by Compound 1, suggesting that innate immune mechanisms are not inhibited by Compound 1. pCRP did not increase phagocytosis of zymosan and E. coli, respectively, phagocytosis, which was also not affected by Compound 1.
Claims
Formula 1 wherein
X1 is selected from -SO3H, -PO3H, and -CO2H;
L1 is selected from -CH2-CH2-, -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, -O-CH2-CH2-, -CH2-CH2-CH2-CH2-, -NH-CH2-CH2-CH2-, -S-CH2-CH2-CH2-, and -O-CH2-CH2-CH2-; and
R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
2. The compound of Formula 1 according to claim 1, wherein:
X1 is selected from -SO3H, -PO3H, and -CO2H;
L1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-; R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
3. The compound of Formula 1 according to claim 1, wherein:
X1 is -SO3H;
L1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-; R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
4. The compound of Formula 1 according to claim 1, wherein:
X1 is -PO3H;
L1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-; R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
5. The compound of Formula 1 according to claim 1, wherein:
X1 is -CO2H;
L1 is selected from -CH2-CH2-CH2-, -NH-CH2-CH2-, -S-CH2-CH2-, and -O-CH2-CH2-; R1 and R2 are each independently selected from C4-2oalkyl, Ci-2oalkylaryl, and Ci- 2oalkylhetaryl.
6. The compound of Formula 1 according to any one of claims 1 to 5, wherein R1 and R2 are each independently be selected from Gmoalkyl, Ci-ioalkylaryl, and Ci-ioalkylhetaryl.
7. The compound of Formula 1 according to any one of claims 1 to 6, wherein R1 and R2 are each independently be selected from C4-ioalkyl, Ci-6alkylaryl, and Ci-6alkylhetaryl.
8. The compound of Formula 1 according to any one of claims 1 to 7, wherein the Ci- 2oalkylaryl is a Ci-2oalkylbenzene.
9. The compound of Formula 1 according to any one of claims 1 to 8, wherein the Ci- 2oalkylhetaryl is a Ci-2oalkylpyridine.
10. The compound of Formula 1 according to claim 1 selected from the following:
11. The compound of any one of claims 1 to 10, wherein the compound is an anti inflammatory agent effective for inhibiting pro-inflammatory effects of C-reactive protein.
12. A pharmaceutical composition comprising a compound of Formula 1, or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any one of claims 1 to 11, and a pharmaceutically acceptable excipient.
13. A method of controlling C-reactive protein levels in a subject comprising administering to the subject an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or stereoisomer thereof, according to any one of claims 1 to 11 or a pharmaceutical composition according to claim 12.
14. The method of claim 13, wherein the controlling of C-reactive protein levels in a subject is by modulating or inhibiting the pro-inflammatory actions of pentameric C-reactive protein (pCRP) or monomeric C-reactive protein (mCRP).
15. A method of preventing or treating a C-reactive protein associated disease, disorder or condition, comprising administering to a subject in need of treatment thereof an effective amount of a compound of Formula 1, or pharmaceutically acceptable salt, solvate or
stereoisomer thereof, according to any one of claims 1 to 11 or a pharmaceutical composition according to claim 12.
16. The method of any one of claims 13 to 15, wherein the C-reactive protein associated disease, disorder or condition, is an ischemia-reperfusion injury including myocardial infarction, stroke, organ or vascular transplants, surgery or injuries, burns, allogenic transplantation, atherosclerotic disease, pericarditis, miocarditis, autoimmune diseases such as Crohn’s disease, ulcerative colitis, rheumatoid arthritis, multiple sclerosis, or diseases associated with inflammation driven by protein misfolding such as amyloidoses, Alzheimer disease, prion diseases and age-related macular degeneration, or diseases associated with overshooting inflammation such as sepsis or COVID-19.
17. The method of any one of claims 13 to 16, wherein the C-reactive protein associated disease, disorder or condition, is an inflammatory disease, disorder or condition.
18. The method of claim 17, wherein the inflammatory disease, disorder or condition is from a bacterial (e.g. sepsis), viral (e.g. COVID-19) or fungal infection, rheumatic disease, malignancy, atherosclerosis, myocardial infarction, tissue injury, or necrosis.
19. The method of any one of claims 13 to 18, wherein the C-reactive protein associated inflammatory disease, disorder or condition, is ischemia-reperfusion injury (IRI).
20. The method of claim 19, wherein the ischemia-reperfusion injury (IRI) is from organ transplantation, vascular surgery, acute ischemic renal injury, or delayed graft function.
21. The method of any one of claims 13 to 18, wherein the C-reactive protein associated disease is a cardiovascular disease.
22. The method of claim 21, wherein the cardiovascular disease or condition is cardiac arrhythmia, vascular disease, myocardial infarction, stroke, congestive heart failure, myocarditis, atherosclerosis, or restenosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021900511A AU2021900511A0 (en) | 2021-02-25 | C-reactive protein inhibitors | |
AU2021900511 | 2021-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022178594A1 true WO2022178594A1 (en) | 2022-09-01 |
Family
ID=83047512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2022/050156 WO2022178594A1 (en) | 2021-02-25 | 2022-02-25 | C-reactive protein inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022178594A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345068A2 (en) * | 1988-06-03 | 1989-12-06 | JOHN WYETH & BROTHER LIMITED | Agonist of gamma-aminobutyric acid |
EP0561175A1 (en) * | 1992-03-18 | 1993-09-22 | Mochida Pharmaceutical Co., Ltd. | Pyrimidine derivatives and pharmaceutical compostions containing them |
US20030171251A1 (en) * | 2000-12-18 | 2003-09-11 | Pepys Mark B. | Treatment and prevention of tissue damage |
WO2003097104A1 (en) * | 2002-05-15 | 2003-11-27 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
WO2009084737A1 (en) * | 2007-12-28 | 2009-07-09 | Interprotein Corporation | Compound having activity to suppress degranulation and cytokine production and use thereof |
-
2022
- 2022-02-25 WO PCT/AU2022/050156 patent/WO2022178594A1/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0345068A2 (en) * | 1988-06-03 | 1989-12-06 | JOHN WYETH & BROTHER LIMITED | Agonist of gamma-aminobutyric acid |
EP0561175A1 (en) * | 1992-03-18 | 1993-09-22 | Mochida Pharmaceutical Co., Ltd. | Pyrimidine derivatives and pharmaceutical compostions containing them |
US20030171251A1 (en) * | 2000-12-18 | 2003-09-11 | Pepys Mark B. | Treatment and prevention of tissue damage |
WO2003097104A1 (en) * | 2002-05-15 | 2003-11-27 | Pentraxin Therapeutics Limited | Treatment and prevention of tissue damage |
US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
WO2009084737A1 (en) * | 2007-12-28 | 2009-07-09 | Interprotein Corporation | Compound having activity to suppress degranulation and cytokine production and use thereof |
Non-Patent Citations (5)
Title |
---|
BAER E. ET AL.: "Phosphonolipids. XV. Synthesis of a dihydroceramide aminoethylphosphonate", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, NRC RESEARCH PRESS, CANADA, vol. 46, no. 3, 30 November 1967 (1967-11-30), CANADA , pages 525 - 532, XP009539506, ISSN: 0008-4212, DOI: 10.1139/y68-076 * |
DATABASE REGISTRY 16 August 2012 (2012-08-16), ANONYMOUS : "-1-Propanesulfonic acid, 3-(dibutylamino)- (CA INDEX NAME) ", XP055966755, retrieved from STN Database accession no. 1391761-97-9 * |
DATABASE REGISTRY 7 October 2011 (2011-10-07), ANONYMOUS : " -Phosphoramidic acid, N-[2-[bis(phenylmethyl)amino]ethyl]- (CA INDEX NAME) ", XP055966757, retrieved from STN Database accession no. 1334586-67-2 * |
MCFADYEN JAMES D., KIEFER JURIJ, BRAIG DAVID, LOSEFF-SILVER JULIA, POTEMPA LAWRENCE A., EISENHARDT STEFFEN ULRICH, PETER KARLHEINZ: "Dissociation of C-Reactive Protein Localizes and Amplifies Inflammation: Evidence for a Direct Biological Role of C-Reactive Protein and Its Conformational Changes", FRONTIERS IN IMMUNOLOGY, vol. 9, XP055966753, DOI: 10.3389/fimmu.2018.01351 * |
PETERSON, M. A. ET AL.: "Thermal Proton Transfer In Crystalline N,N- Dialkylated Amino Acids", THE JOURNAL OF PHYSICAL CHEMISTRY, vol. 89, 1985, pages 522 - 524, XP055964603 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102533599B1 (en) | Protein tyrosine phosphatase inhibitors and methods of use thereof | |
JP7175026B2 (en) | 1H-imidazo[4,5-H]quinazoline compounds as protein kinase inhibitors | |
EP2176259B1 (en) | Fused imidazoles for cancer treatment | |
EP2847180B1 (en) | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer | |
EP3010901B1 (en) | Heteroaryl substituted pyrazoles | |
KR20210005222A (en) | RIP1 inhibitory compounds and methods of making and using them | |
AU2017370694A1 (en) | Compositions and methods for treating CDK4/6-mediated cancer | |
TWI827641B (en) | Tlr7/8 antagonists and uses thereof | |
US9260435B2 (en) | Substituted imidazopyrazines as Akt kinase inhibitors | |
CN103896942A (en) | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) | |
EP3271362B1 (en) | Heterocyclic compounds useful as inhibitors of tnf | |
CN106132968B (en) | It is a kind of for prevent or treating cancer inhibition bromine structural domain compound and containing the pharmaceutical composition of the compound | |
US20220227775A1 (en) | 1h-pyrazolo[4,3-h]quinazoline compound serving as protein kinase inhibitor | |
JP2022523358A (en) | Kinase inhibitor | |
JP2023512040A (en) | Compounds and uses thereof | |
CN114867473A (en) | Salt forms of the complement component C5A receptor | |
KR20200035982A (en) | Compounds and uses thereof for the prevention and treatment of medical disorders | |
WO2022178594A1 (en) | C-reactive protein inhibitors | |
JP6586463B2 (en) | Heterocycle-linked imidazopyridazine derivatives as PI3Kβ inhibitors | |
EP3929188A1 (en) | Pd-l1 antagonist compound | |
US9370517B2 (en) | Substituted pyrazolopyrimidines as Akt kinase inhibitors | |
US8987286B2 (en) | Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway | |
EP2730575B1 (en) | Crystal form i of salt of dipeptidyl peptidase-iv inhibitor and preparation method and use thereof | |
CN111712246A (en) | Bis (hydroxymethyl) pyrrolophthalazine heterozygote, preparation method and application thereof | |
WO2024056005A1 (en) | Polycyclic compound and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22758647 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22758647 Country of ref document: EP Kind code of ref document: A1 |